ORG_CITY: MUNCIE

ORG_NAME: EARLY IS GOOD INC.

ORG_STATE: IN

PHR: BCDx is a diagnostic assay that is designed and optimized to inform on the recurrence of bladder cancer from a patient urine sample. Integration of BCDx into the standard of care is expected to identify bladder cancer recurrence earlier and accurately, thereby improving the chances of successful treatment.

PI_NAMEs: LIYANAGE, THAKSHILA  (contact)

PROGRAM_OFFICER_NAME: BOZZA, WILLIAM PATRICK

PROJECT_TERMS: Address;Adoption;Aftercare;Antigens;Arkansas;Biological Assay;Biological Markers;cancer biomarkers;cancer care;Cancer Patient;cancer recurrence;Characteristics;Classification;Clinic;Clinical;Clinical Research;Collaborations;commercialization;Complement;Consent;Cystoscopy;Cytology;Data;data acquisition;design;detection method;Development;Diagnosis;Diagnostic;diagnostic accuracy;diagnostic assay;Diagnostic tests;Disease;Disease Progression;Early Diagnosis;empowerment;Exhibits;FDA approved;Feasibility Studies;Foundations;Future;Goals;Guidelines;Health;Health Professional;healthy volunteer;Hour;improved;Indiana;International;Investments;Laboratories;Legal patent;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Measures;Medical;Messenger RNA;Methods;MicroRNAs;Molecular;Molecular Diagnostic Testing;Monitor;multiple omics;muscle invasive bladder cancer;Nanotechnology;National Comprehensive Cancer Network;Neoplasms;non-muscle invasive bladder cancer;noninvasive diagnosis;novel strategies;Oncogenic;Pain;Pathway interactions;Patient Care;Patients;Performance;Phase;Predictive Value;Procedures;Prospective Studies;Proteins;Recommendation;Recurrence;Recurrent disease;Reporting;Research;Resources;RNA;Sampling;screening;Secure;Sensitivity and Specificity;sound;Special Equipment;Specificity;standard of care;Surveillance Methods;Technology;Testing;Time;tumor;Tumor Suppressor Proteins;Universities;Urine;Urology;validation studies;Washington

PROJECT_TITLE: Multiplex and multi-omic diagnostic test for bladder cancer recurrence

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CDPT-V (13)]


ADMINISTERING_IC: HL

ARRA_FUNDED: N

FUNDING_MECHANISM: SBIR-STTR RPGS

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Asthma;Chronic Obstructive Pulmonary Disease;Cystic Fibrosis;Lung;Orphan Drug;Rare Diseases

ORG_CITY: DURHAM

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: PARION SCIENCES, INC.

ORG_STATE: NC

PHR: PROJECT NARRATIVE Muco-obstructive lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma, typically reflect the accumulation of hyperconcentrated, poorly clearable mucus in the lung that ultimately leads to airflow obstruction, inflammation, and infection. Muco-obstructive lung diseases are amongst the major diseases that contribute to health problems in the United States and there are no specific therapies designed to clear accumulated mucus from the lungs of these patients. This application outlines a proposal for the development of a novel inhaled agent to restore the hydration of mucus in muco-obstructed patients and potentially restore health to these patients.

PI_NAMEs: DONN, KARL H (contact)

PROGRAM_OFFICER_NAME: LACHOWICZ-SCROGGINS, MARRAH ELIZABETH

PROJECT_TERMS: Acceleration;ADME Study;Aerosols;airway epithelium;airway obstruction;Animal Disease Models;Asthma;asthmatic;beta-Cyclodextrins;Binding;Binding Proteins;biophysical analysis;Bronchiectasis;Canis familiaris;Categories;channel blockers;Characteristics;Chronic;Chronic Obstructive Pulmonary Disease;Clinic;Clinical;Clinical Research;Combined Modality Therapy;Cystic Fibrosis;cystic fibrosis airway;cystic fibrosis mucus;Cystic Fibrosis Transmembrane Conductance Regulator;Data;Dedications;Defect;design;Development;Development Plans;Disease;Dose;Drug Formulations;Drug Kinetics;efficacy study;efficacy testing;epithelial Na+ channel;Epithelium;Etiology;Excretory function;experience;Failure;Fluids and Secretions;Formulation;Genetic;Goals;Health;Hepatic;Human;Hydration status;improved;In Vitro;Infection;Inflammation;Inhalation;Inhalation Drug Administration;Inhalation Toxicology;innovation;Ion Transport;Ions;Kidney;Kinetics;Liquid substance;Lung;manufacture;Mediating;Metabolism;mortality;mouse model;Mucins;Mucociliary Clearance;Mucous body substance;mucus clearance;mucus-associated lung diseases;new chemical entity;next generation;novel;Obstruction;Osmosis;Osmotic Activity;Osmotic Pressure;Pathogenesis;Pathway interactions;Patients;Permeability;Pharmaceutical Chemistry;Pharmaceutical Preparations;Phase;phase 1 study;phase 2 study;phase II trial;Physics;Plasma Proteins;Polymers;Population;pre-clinical;preservation;Primary Ciliary Dyskinesias;primary endpoint;prototype;Pulmonary Cystic Fibrosis;Pulmonary Function Test/Forced Expiratory Volume 1;Rattus;Recording of previous events;Research Design;research study;Respiratory Disease;Respiratory Failure;response;Safety;Saline;Science;Small Business Innovation Research Grant;success;Surface;Testing;Therapeutic;Therapeutic Agents;therapy design;Toxic effect;United States

PROJECT_TITLE: A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 RCCS-B (11)]


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Drug Abuse (NIDA only);Fentanyl Misuse and Addiction;Neurosciences;Opioid Misuse and Addiction;Opioids;Substance Misuse

ORG_CITY: ENCINTIAS

ORG_NAME: ELEVEN THERAPEUTICS CORP

ORG_STATE: CA

PHR: Project Narrative Opioid Abuse Disorder (OUD) is a serious problem in the United States and throughout the world, with increasing harm and burden to the individual, their families and society. Therefore, there is a major unmet need for more efficient and effective methods to help patients suffering from OUD. In this project we will develop a series of medications that target the opioid receptor in a novel fashion to manage OUD, while avoiding the problems (abuse liability and/or patient compliance) of currently approved treatment medications.

PI_NAMEs: TRAYNOR, JOHN R. (contact)

PROGRAM_OFFICER_NAME: SABIRZHANOV, BORIS YEVGENYEVICH

PROJECT_TERMS: abuse liability;Address;Agonist;Ames Assay;Anhedonia;antagonist;antinociception;Back;Behavior;Biological Assay;Biological Availability;blood-brain barrier penetration;Brain;Buprenorphine;Canis familiaris;Capital;Cessation of life;Characteristics;chemical synthesis;Chemicals;Chemistry;clinical candidate;Clinical Trials;Cues;Data;Development;Disease;Dose;Drug Metabolic Detoxication;drug seeking behavior;Emergency medical service;Ensure;expectation;experience;Family;Female;Fentanyl;fentanyl seeking;Funding;Goals;Grant;head-to-head comparison;Human;improved;In Vitro;in vitro activity;in vivo;Individual;Knowledge;Lead;lead optimization;Liver Microsomes;Maintenance;male;Measures;Medical;medication for opioid use disorder;metabolic profile;Metabolism;Methadone;Methods;Modeling;Modification;Morphine;Motivation;mu opioid receptors;Mus;Naltrexone;novel;Opioid;opioid abuse;Opioid agonist;Opioid Antagonist;opioid overdose;Opioid Receptor;opioid use disorder;Oral;Overdose;overdose death;Patient Compliance;Patient-Focused Outcomes;Patients;Penetration;Pharmaceutical Preparations;Phase;Positioning Attribute;Property;Rattus;receptor;Relapse;relapse prevention;Reporting;Research;Respiration;Risk;Schedule;Self Administration;Series;side effect;Site;Small Business Technology Transfer Research;Societies;standard of care;System;Testing;Toxic effect;Toxicology;United States;United States National Center for Health Statistics;Ventilatory Depression;Withdrawal;Withdrawal Symptom;Work

PROJECT_TITLE: Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-S (14)]


FUNDING_MECHANISM: OTHER RESEARCH-RELATED

NIH_SPENDING_CATS: Behavioral and Social Science;Clinical Research;Clinical Trials and Supportive Activities;Dissemination and Implementation Research;Drug Abuse (NIDA only);Emergency Care;HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Infectious Diseases;Mental Health;Networking and Information Technology R&D (NITRD);Prevention;Racial and Ethnic Minority Health Research;Social Determinants of Health;Substance Misuse;Telehealth

ORG_CITY: BOSTON

ORG_NAME: BRIGHAM AND WOMEN'S HOSPITAL

ORG_STATE: MA

PHR: PROJECT NARRATIVE Despite nationally declining rates and efficacious interventions for HIV prevention, services are not reaching minoritized people who use drugs who continue to face high incidence. Leveraging syndemic theory, consultation-liaison psychology, emergency departments, and mHealth, the goal of this project is to develop a low threshold, real-world, multilevel HIV prevention approach. This study is consistent with national Ending the HIV Epidemic goals and NIH priorities for HIV/AIDS research, by aiming to optimize and improve how we serve those at high risk for being missed by and/or falling off the HIV prevention cascade.

PI_NAMEs: GLYNN, TIFFANY ROSE (contact)

PROGRAM_OFFICER_NAME: JENKINS, RICHARD A

PROJECT_TERMS: Accident and Emergency department;Address;AIDS prevention;Area;arm;barrier to care;Behavior Therapy;Behavioral Medicine;Black race;Caring;Clinic;Clinical;Cognitive Therapy;Collaborations;community advisory board;Consolidated Framework for Implementation Research;Consultations;Cross-Sectional Studies;Data;design;Development;Diabetes Mellitus;digital health;Discipline;Discrimination;dosage;Dose;Drops;Drug usage;Drug user;efficacious intervention;Eligibility Determination;Emergency department visit;Environment;Epidemic;experience;falls;Feedback;Focus Groups;Goals;Health behavior;health care settings;health disparity;health equity;Health Priorities;Health Services Accessibility;Health Technology;Height;high risk;HIV;HIV disparities;HIV Infections;HIV risk;HIV Seropositivity;HIV/AIDS;Home;Hospitals;Housing;Human;Human immunodeficiency virus test;implementation outcomes;implementation science;improved;Incidence;Indigenous;Individual;innovation;integrated care;Intervention;Interview;Latinx;Leadership;Logistics;marginalization;marginalized population;men who have sex with men;Mental Health;Methods;mHealth;minority engagement;Minority Groups;minority stress;model design;motivational enhancement therapy;National Institute of Drug Abuse;Participant;Pathway interactions;Patients;peer;Persons;Pharmacotherapy;pilot test;Population;precision medicine;Prevention;Prevention approach;preventive intervention;Process;Psychology;psychosocial;Research;Resources;Risk;Risk Behaviors;Scientist;Series;seroconversion;Service delivery model;Services;social stigma;Surveys;Symptoms;syndemic;Telephone;Testing;theories;Time;tool;Training;transgender women;United States National Institutes of Health;uptake;user centered design;Wait Time

PROJECT_TITLE: Leveraging mHealth to develop syndemic-based behavioral medicine HIV prevention for the emergency department to reach minoritized PWUD

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 SCIL-A (03)]


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Biotechnology;Cancer;Hematology;Immunotherapy;Orphan Drug;Prevention;Rare Diseases;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation

ORG_CITY: CHICAGO

ORG_NAME: HASENTECH, INC.

ORG_STATE: IL

PHR: Graft versus host disease (GvHD) is a frequent outcome of hematopoietic stem cell transplants used to treat hematologic diseases, such as leukemia. Even after prophylactic drug treatment, up to 60% of these transplant patients suffer from GvHD. We have identified a means of reducing GvHD by administering cells pre-treated with a purified bacterial molecule, exopolysaccharide (EPS). EPS is non-toxic and the goal of this grant is develop EPS-DCs as a therapeutic agent to attenuate GvHD in humans.

PI_NAMEs: KNIGHT, KATHERINE L. (contact);OSBORNE, BARBARA A

PROGRAM_OFFICER_NAME: MINNICOZZI, MICHAEL

PROJECT_TERMS: Acute;Aftercare;Allogenic;Attenuated;B-Lymphocytes;Biological Markers;Blocking Antibodies;CD34 gene;Cell Therapy;Cell Transplantation;Cells;chronic graft versus host disease;commercialization;Complication;Cryopreservation;Cyclophosphamide;Data;Dendritic Cell Therapy;Dendritic Cells;Disease;Dose;Engineering;Exposure to;Foundations;Freezing;Generations;Goals;graft vs host disease;graft vs leukemia effect;Grant;Hematologic Neoplasms;Hematological Disease;Hematopoietic Stem Cell Transplantation;Hematopoietic stem cells;HLA-A2 Antigen;Human;humanized mouse;Immunologics;improved;In Vitro;in vivo;Inflammatory;inhibitor;Intervention;Label;Legal patent;Letters;leukemia;Leukemic Cell;Licensing;Luciferases;Macrophage;manufacture;Massachusetts;Mediating;Mixed Lymphocyte Culture Test;Modification;Molecular;mouse model;Mus;Names;Natural Killer Cells;novel;Organ;Outcome;Patients;Peripheral Blood Mononuclear Cell;Pharmaceutical Preparations;Pharmacotherapy;Phase;post-transplant;pre-clinical;Preparation;prevent;Prevention;Prevention therapy;Probiotics;prophylactic;Protocols documentation;Quality Control;Regimen;Small Business Innovation Research Grant;Small Business Technology Transfer Research;Standardization;System;T-Cell Proliferation;T-Lymphocyte;Technology;Testing;Therapeutic Agents;Time;Translating;Transplant Recipients;Transplantation;transplantation therapy;treatment optimization;Universities;Xenograft Model

PROJECT_TITLE: Dendritic cell therapy for GvHD


ADMINISTERING_IC: VA

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: Veterans Affairs

ORG_CITY: NASHVILLE

ORG_NAME: VETERANS HEALTH ADMINISTRATION

ORG_STATE: TN

PHR: Helicobacter pylori infection is common among Veterans, and Veterans are at risk for development of H. pylori- induced diseases such as stomach cancer and peptic ulcers. During travel to various parts of the world, Veterans are at risk for acquiring H. pylori strains that confer a relatively higher risk of gastric cancer compared to strains found in the United States. The Veterans Administration currently spends millions of dollars each year for acid-suppressive drug regimens to prevent or treat H. pylori-related complications, and the treatment of H. pylori infection with antibiotics is challenging due to a continually increasing proportion of antibiotic- resistant strains. Investigation of the molecular mechanisms by which H. pylori colonizes the human stomach and causes gastric diseases is likely to lead to the development of new approaches for the prevention and treatment of H. pylori infection, which would have important clinical implications for the care of Veterans.

PI_NAMEs: COVER, TIMOTHY L (contact)

PROJECT_TERMS: Ablation;Acids;Adherence;Animals;Antibiotic Resistance;Antibiotics;Bacteria;Bacterial Adhesins;Bar Codes;Binding Proteins;Cancer Etiology;Carcinogens;Caring;Cells;Cessation of life;Clarithromycin;Classification;Clinical;Complex;Development;Diet;dietary;Disease;disorder prevention;Duodenal Ulcer;Enzymes;Epithelial Cells;experimental study;Family;fitness;Funding;Gastric Adenocarcinoma;Gastric lymphoma;Gastric mucosa;Gastric Tissue;Gastric ulcer;Genes;Genome;Gerbils;Goals;Gram-Negative Bacteria;Helicobacter Infections;Helicobacter pylori;Helicobacter pylori associated gastric disease;high risk;Hop protein;Human;In Vitro;in vivo;Individual;Inductively Coupled Plasma Mass Spectrometry;Infection;Investigation;Iron;Lasers;malignant stomach neoplasm;Mediating;Membrane;Membrane Proteins;Metals;Methods;Molecular;mouse model;Mus;Mutagenesis;mutant;Mutate;Mutation;Nickel;novel strategies;Nucleotides;Nutrient;Pathogenesis;Peptic Ulcer;periplasm;Pharmaceutical Preparations;Population;prevent;Prevention approach;Prevention strategy;Process;Property;protein function;Proteins;Proton-Motive Force;Regimen;Regulation;Reporting;Resistance;resistant strain;Risk;Role;Sequence Analysis;Signal Transduction;Spatial Distribution;Stomach;Stomach Diseases;Structure;Surface;System;Testing;Travel;United States;United States Department of Veterans Affairs;uptake;Urease;Veterans;Work;World Health Organization

PROJECT_TITLE: "Pathogenesis of Helicobacter pylori Infection"

STUDY_SECTION_NAME: Special Emphasis Panel[ZRD1 INFB-K (01)]


ADMINISTERING_IC: CA

ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

IC_NAME: NATIONAL CANCER INSTITUTE

ORG_CITY: Nashville

ORG_DEPT: CHEMISTRY

ORG_NAME: VANDERBILT UNIVERSITY

PHR: Public Narrative Under this project, we will further develop and validate an emerging platform technology that can be used to measure molecular interactions, in complex matrices, such as serum and urine, without altering the sample and at unprecedented sensitivity. Preliminary observations indicate that the Mix-and-Read, free-solution assay methodology can be used widely, with the potential to accelerate and/or enhance research in the areas of drug discovery, cancer biology, early detection and screening, and clinical diagnosis.

PI_NAMEs: BORNHOP, DARRYL J. (contact)

PROGRAM_OFFICER_NAME: BECKER, STEVEN

PROJECT_TERMS: Acceleration;Address;Adoption;anti-cancer research;Antibodies;aptamer;Area;assay development;Automation;Base Pairing;Binding;Biochemical;Biological Assay;Biological Markers;biomarker discovery;biomarker performance;biomarker validation;Biotechnology;Blood capillaries;Buffers;Calibration;Cancer Biology;cancer biomarkers;Cells;Clinical;clinical diagnosis;Communities;Compensation;Complex;Computer software;Data;Data Analyses;Data Collection;Dependence;detector;Development;Diagnostic;Dose;drug development;drug discovery;Drug Targeting;Early Diagnosis;early screening;Enzyme-Linked Immunosorbent Assay;Enzymes;Erythrocytes;first-in-human;Fluorescence;Immobilization;improved;In Vitro;instrument;Label;Lasers;Legal patent;Length;Letters;Malignant Neoplasms;Measurement;Measures;Meconium;Medical;Membrane Proteins;Methodology;Methods;Molecular;Molecular Analysis;Nature;Noise;novel;operation;Optics;Performance;Pharmaceutical Preparations;Phase;Physiological;Plasma;Preparation;prognostic;programs;Property;protein biomarkers;protein protein interaction;prototype;Publishing;Quintuplet Multiple Birth;Reader;Recovery;Refractive Indices;Reproducibility;Research;Retinal blind spot;Robot;Running;Sampling;Scheme;sensor;Serum;Signal Transduction;Speed;Technology;technology development;technology platform;Testing;theranostics;Tissues;tool;Training;Translating;Tube;Update;Urine;user-friendly;Validation

PROJECT_TITLE: Quantification of molecular interactions across the matrix spectrum enables cancer research.

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 TCRB-D (M2)]


ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Basic Behavioral and Social Science;Behavioral and Social Science;Bioengineering;Brain Disorders;Clinical Research;Dementia;Eye Disease and Disorders of Vision;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Networking and Information Technology R&D (NITRD);Neurodegenerative;Neurosciences;Patient Safety;Primary Health Care;Racial and Ethnic Minority Health Research;Social Determinants of Health

ORG_CITY: NEW YORK

ORG_NAME: CLEAR SESSION, INC.

ORG_STATE: NY

PHR: Project Narrative Clear Session, Inc will develop an innovative digital visualization solution to increase engagement among Latino ADRD patients, their caregivers and healthcare providers. We have a collaboration with UTHealth Houston to provide the academic background to tool development

PI_NAMEs: HAACKE, CARL  (contact);SAMPER-TERNENT, RAFAEL

PROGRAM_OFFICER_NAME: HARRELL, ERIN

PROJECT_TERMS: Address;Adherence;Age;Alzheimer's disease patient;Alzheimer's disease related dementia;animation;care providers;care seeking;Caregivers;Caring;Client satisfaction;Clinic;Clinical;clinical encounter;Collaborations;commercialization;Communication;Communication Barriers;community organizations;Community Outreach;computer human interaction;Computerized Medical Record;contextual factors;cost;cultural competence;Data;dementia care;design;Development;Diagnosis;digital;digital tool;disparity reduction;Education;efficacy evaluation;Elements;ethnic disparity;Face;Family member;Feedback;Foundations;Friends;Health;health disparity;health literacy;Health Personnel;Healthcare;Healthcare Systems;Hospitalization;improved;individual patient;innovation;iterative design;Language;Latino;Latino Population;Linguistics;literacy;mathematical ability;member;neuropsychiatric symptom;Patient Care;patient navigator;patient oriented;patient safety;patient-clinician communication;Patients;Persons;Phase;poor health outcome;primary care provider;Process;prototype;Provider;Quality of Care;Quality of life;racial disparity;Recommendation;Research;Resources;Science;Spanish;Tablet Computer;Testing;Text;Time;tool;tool development;Translations;Trust;usability;vision development;Visit;Visual;Visual Aid;Visualization;Visualization software

PROJECT_TITLE: Personalized visualization tool to improve communication between clinicians, Latinos with ADRD, and their care partners

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CCHI-J (10)]


ED_INST_TYPE: SCHOOLS OF VETERINARY MEDICINE

NIH_SPENDING_CATS: Antimicrobial Resistance;Biodefense and Related Countermeasures;Emerging Infectious Diseases;Infectious Diseases;Lung;Orphan Drug;Rare Diseases;Tuberculosis

ORG_CITY: FORT COLLINS

ORG_DEPT: MICROBIOLOGY/IMMUN/VIROLOGY

ORG_NAME: COLORADO STATE UNIVERSITY

ORG_STATE: CO

PHR: Project Narrative The emergence and global spread of multidrug resistant and extensively drug resistant tuberculosis (MDR/XDRTB) is of great concern to global health. MDR/XDR-TB chemotherapy can cause serious side effects. The approach studied here is to develop therapies with aerosols of spectinamides, known for their robust efficacy in vivo and excellent safety profile, within new regimens of TB therapy for treatment of MDR-XDR TB and drug susceptible-TB.

PI_NAMEs: GONZALEZ-JUARRERO, MERCEDES  (contact);MALONEY, SARA ELIZABETH;MEIBOHM, BERND

PROGRAM_OFFICER_NAME: BOYCE, JIM P

PROJECT_TERMS: Adverse effects;Adverse event;Aerosols;Anemia;Animal Model;Animals;Antitubercular Agents;Antitubercular Antibiotics;bactericide;Biological Availability;C3HeB/FeJ Mouse;Canis familiaris;Clinical Pathology;Clinical Trials;Colorado;commercialization;companion animal;comparative;Data;Devices;Disease;Dose;Drug Combinations;drug development;Drug Kinetics;Drug Modelings;Drug or chemical Tissue Distribution;Drug resistant Mycobacteria Tuberculosis;drug-sensitive;Dryness;efficacy evaluation;extensive drug resistance;Extreme drug resistant tuberculosis;follower of religion Jewish;Formulation;Frequencies;global health;Goals;Health;Human;improved;In Vitro;in vivo;Inbred BALB C Mice;Inhalation;Inhalation Drug Administration;Inhalation Therapy;Inhalators;Injectable;International;Lead;Linezolid;Lung;manufacture;Modeling;Monitor;Multi-Drug Resistance;Mus;Mycobacterium tuberculosis;Myelosuppression;novel strategies;Oral;Oral Tuberculosis;Organ;Oxazolidinones;Patient Compliance;Patients;Penetration;Performance;Pharmaceutical Chemistry;Pharmaceutical Preparations;Pharmacotherapy;Physicians;pill;Powder dose form;pre-clinical;Preclinical Testing;Predisposition;Preparation;Production;Property;Protein Synthesis Inhibitors;Pyrazinamide;Rattus;Regimen;Reporting;Resistance;resistant strain;Rifampin;Route;Safety;safety study;Saint Jude Children's Research Hospital;side effect;simulation;Sterility;Sterilization;Tennessee;Testing;Therapeutic;therapy development;Tissues;Toxic effect;Toxicology;Tuberculosis;tuberculosis chemotherapy;tuberculosis drugs;tuberculosis treatment;Universities;Work

PROJECT_TITLE: Inhalational therapy with spectinamides within new regimens of TB therapy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-M (81)]


PHR: Colorectal cancer (CRC) is the 3rd most common cancer and 2nd leading cause of death in men and women combined, and colitis-associated cancer (CAC) is a subset. Multiple studies have suggested a link between CRC and bacterial factors or inflammation, and the link between inflammatory bowel disease (IBD) and colonic pre-cancerous lesions and cancer itself is firmly established. The cumulative probability of developing cancer in ulcerative colitis depends greatly on disease duration, and is 2% by 10 years, 8% by 20 years, and 18% by 30 years. The prevalence of IBD is increasing among VA healthcare system users. Veterans with IBD develop CRC at a younger age and are more likely to develop right-sided colon cancer. CRC, including CAC, represents a significant health problem for our Veterans. Therefore, there is an ongoing need to discover new approaches for improving patient risk stratification and/or novel treatment strategies; we aim to establish CCL11 as an important target.

PI_NAMEs: COBURN, LORI A (contact)

PROJECT_TERMS: Acute;Adult;Affect;Age;American;Animals;Antibodies;APC gene;Apoptosis;Azoxymethane;Behavior;Cancer Model;carcinogenesis;carcinogenicity;Cause of Death;Cell Physiology;Cells;Chemotactic Factors;Clinical;cohort;Colitis;colitis associated cancer;Colitis associated colorectal cancer;Colon;colon cancer cell line;Colon Carcinoma;Colorectal Cancer;Crohn's disease;cytokine;Data;Development;dextran sulfate sodium induced colitis;disorder control;DNA Damage;DNA Sequence Alteration;eosinophil;Eotaxin;Epithelial Cells;epithelial wound;Epithelium;Exhibits;Exposure to;Functional disorder;Future;Gene Expression Profile;Genetic;HCT116 Cells;Health;Healthcare Systems;Histologic;Human;illness length;Immune response;improved;Infiltration;Inflammation;Inflammatory;Inflammatory Bowel Diseases;Injury;insight;knock-down;Lesion;Link;Malignant Neoplasms;MAP Kinase Gene;Mediating;men;Modeling;Molecular;Morbidity - disease rate;mouse model;Mus;novel;novel strategies;novel therapeutic intervention;novel therapeutics;Oncogenic;Organoids;Patient risk;Patients;Phenotype;premalignant;Prevalence;Probability;prospective;receptor;Recombinants;Reporting;risk stratification;Role;Sampling;Serum;Severity of illness;Side;Signal Pathway;Signal Transduction;Sodium Dextran Sulfate;Somatic Mutation;Testing;Tissues;treatment strategy;tumor;Tumor Burden;Tumor Promotion;tumorigenesis;Ulcerative Colitis;Veterans;Woman

PROJECT_TITLE: The Role of CCL11 in Inflammatory and Sporadic Colorectal Cancer.

STUDY_SECTION_NAME: Special Emphasis Panel[ZRD1 ONCC-S (01)]


ED_INST_TYPE: SCHOOLS OF MEDICINE

NIH_SPENDING_CATS: Aging;Clinical Research;Lung;Organ Transplantation;Patient Safety;Transplantation

ORG_CITY: SAN FRANCISCO

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

PHR: PROJECT NARRATIVE This mid-career mentoring award will provide Dr. Jonathan Singer protected time and support to pursue career development activities and to investigate the impact of newly described molecular subphenotypes of frailty on key clinical and patient-reported outcomes before and after lung transplantation. He will leverage this training and new scientific area of inquiry to identify and mentor medicine and surgical subspecialty trainees committed to aging research, especially those seeking to develop independent patient-oriented research careers.

PI_NAMEs: SINGER, JONATHAN PAUL (contact)

PROGRAM_OFFICER_NAME: KALANTARI, ROYA

PROJECT_TERMS: Acceleration;Acute Lung Injury;Acute Respiratory Distress Syndrome;Age;Aging;aging mechanism;aging related;Allografting;Area;Asthma;Award;Biological;Biological Markers;career;career development;Cessation of life;Chronic;Chronic Kidney Failure;Clinical;Cohort Studies;Collaborations;Communities;comorbidity;Complex;Country;Critical Illness;Data;data infrastructure;Delirium;design;Development;Development Plans;disability;disability risk;Discipline of Nursing;Disparity;Environment;Evaluation;evidence base;experience;Exposure to;Eye;Faculty;Feedback;fitness;frailty;Functional disorder;Funding;Geriatrics;Gerontology;Graft Rejection;Guidelines;health related quality of life;Health Services;Heterogeneity;high dimensionality;high risk;hospital readmission;Hospitalization;human old age (65+);improved;Inflammation;Inflammatory;Injury to Kidney;insight;interest;International;Intervention;Lead;Leadership;Learning;Length of Stay;longitudinal dataset;Lung Diseases;Lung Transplantation;Malnutrition;Measures;Medicine;Mentors;Mentorship;Methods;mid-career faculty;Mitochondria;Molecular;molecular phenotype;mortality;Multicenter Studies;novel;Obesity;older adult;Operative Surgical Procedures;Organ Transplantation;Outcome;Participant;participant enrollment;Pathway interactions;patient oriented research;Patient Outcomes Assessments;Patient-Focused Outcomes;Patients;Perioperative;Perioperative complication;Pharmaceutical Preparations;Phenotype;Positioning Attribute;post-transplant;Postoperative Complications;Postoperative Period;Professional Organizations;programs;Pulmonology;Recommendation;Research;Research Infrastructure;Research Personnel;Resources;Risk;Risk Factors;risk stratification;sarcopenia;Seasons;Seminal;Solid;Stress;Structure;Surgical complication;surgical risk;Syndrome;systemic inflammatory response;Testing;Therapeutic;Time;tool;Training;Transplant Recipients;Transplantation;trend;United States National Institutes of Health;Waiting Lists;Work

PROJECT_TITLE: Molecular phenotypes of frailty in lung transplantation

STUDY_SECTION: MPOR

STUDY_SECTION_NAME: NHLBI Mentored Patient-Oriented Research Study Section[MPOR (MA)]


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

ORG_CITY: MCLEAN

ORG_NAME: NEUROLOGIC SOLUTIONS, INC.

ORG_STATE: VA

PHR: Project Narrative An estimated 5 million people worldwide receive a diagnosis of epilepsy annually, and misdiagnosis rates range between 20% to 42% because no reliable biomarker for epilepsy exists. In the proposed Phase 2 SBIR study, we will further develop and validate EpiScalp, a revolutionary EEG analytics algorithm that computes the first reliable scalp EEG marker for epilepsy, with two prospective studies conducted at three well known epilepsy centers in the US. Additionally, we will assess usability of EpiScalp and develop a comprehensive regulatory and rollout plan in partnership with experts from DIXI Medical.

PI_NAMEs: GOTSHALK, ANDREW  (contact);HARIDAS, BABITHA ;HOPP, JENNIFER L.;SPERLING, MICHAEL R

PROGRAM_OFFICER_NAME: CAPORELLO, EMILY LAURA

PROJECT_TERMS: accurate diagnosis;Admission activity;Adverse reactions;Agreement;Algorithms;Ancillary Study;Anticonvulsants;Beds;Biological Markers;Blinded;Brain;Brain region;Businesses;Caring;Cessation of life;Clinical;Collaborations;Consensus;Data;design;Development;Devices;Diagnosis;diagnostic accuracy;Electroencephalography;Employment;empowerment;Environment;Epilepsy;epileptiform;Evaluation;experience;Failure;follow-up;Hour;improved;Intractable Epilepsy;Label;Marketing;Masks;Measures;Medical;Modeling;Monitor;Morphologic artifacts;network models;Neurologic Examination;novel;Observational Study;Operative Surgical Procedures;Patient Triage;Patients;payment;Performance;Persons;Phase;pre-clinical;prediction algorithm;premature;preservation;prospective;Prospective Studies;Quality of Care;Recording of previous events;Recurrence;Research;Resources;Rest;Risk;Running;Scalp structure;Seizures;Small Business Innovation Research Grant;social;social stigma;Source;Specificity;Status Epilepticus;Testing;Time;tool;Triage;usability;Visit;Visual

PROJECT_TITLE: EpiScalp: An EEG Analytics Solution to Improve Diagnosis of Epilepsy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-C (10)]


ADMINISTERING_IC: DK

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

NIH_SPENDING_CATS: Chronic Pain;Pain Research;Urologic Diseases

ORG_NAME: DOLOR THERAPEUTICS, LLC

PHR: Chronic prostatitis/Chronic pelvic pain syndrome (CP/CPPS) is the most common urological condition affecting men under the age of 50. The impact of CP/CPPS on quality of life is comparable to myocardial infarction, Crohn’s disease, congestive heart failure and diabetes mellitus. However, despite this, there are no FDA approved therapeutics for CPPS. This project will address this unmet medical need by performing feasibility studies to develop and test a novel co-formulation for this condition. The proposed work will inform future dosing in humans as well as optimize the formulation to achieve enhanced benefit to patients and a pathway to further commercial development.

PI_NAMEs: SARGENT, WILLIAM Q (contact);THUMBIKAT, PRAVEEN

PROGRAM_OFFICER_NAME: CONAGE-POUGH, JASON EDWARD

PROJECT_TERMS: absorption;Adrenergic alpha-Antagonists;Affect;Aftercare;Age;allodynia;Animal Model;antagonist;anti-depressive agents;Autoimmune;Biological Availability;Blood;Businesses;Canis familiaris;capsule;chronic pelvic pain;Chronic Prostatitis;Clinical;Clinical Research;Collection;Complement;Congestive Heart Failure;Consent;Crohn's disease;Cromoglicic Acid;Cromolyn Sodium;Development;Diabetes Mellitus;Direct Costs;Doctor of Philosophy;Dose;drinking water;Drug Exposure;Drug Kinetics;Drug Targeting;Duodenum;Endoscopes;Enhancers;Enteral;Evaluation;Facilities and Administrative Costs;FDA approved;Feasibility Studies;Formulation;Foundations;Functional disorder;Future;Gastrointestinal tract structure;Gel;Goals;Half-Life;High Prevalence;Histamine Receptor;Hour;Human;Intestinal permeability;Knowledge;Laboratories;Lead;male;manufacture;mast cell;Mast Cell Stabilizer;Medical;men;men who have sex with men;mouse model;Myocardial Infarction;novel;Oral;Pain;Pathway interactions;Patient Compliance;Patients;Pelvic Pain;Pharmaceutical Preparations;Pharmacodynamics;Pharmacologic Substance;Phase;Physical therapy;Pilot Projects;Plasma;Population;Positioning Attribute;Prevalence;Prostatic;prostatitis;Quality of life;reduce symptoms;Reporting;Research;Research Personnel;response;Sampling;Small Business Technology Transfer Research;standard of care;Study models;Symptoms;Tablets;Tactile;Testing;Therapeutic;Therapeutic Agents;Tissues;Translations;Treatment Efficacy;Treatment Protocols;Tryptase;United States National Institutes of Health;Universities;urinary;urologic;Urologist;Withdrawal;Work

PROJECT_TITLE: Optimizing Dual Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 KUDS-R (11)]


ADMINISTERING_IC: DE

IC_NAME: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH

NIH_SPENDING_CATS: Biotechnology;Clinical Research;Dental, Oral, and Craniofacial Disease;Genetics;Human Genome;Infectious Diseases;Microbiome

ORG_CITY: PASADENA

ORG_NAME: BRANCHPOINT BIOSCIENCES INC.

PHR: The oral microbiome is vital for dental health and provides insights into systemic conditions. While next-generation sequencing has limitations for biomarker discovery, qPCR-based molecular detection can offer specificity, sensitivity, and quantification. The development of a comprehensive oral qPCR panel using this technology can provide a cost-effective and efficient research tool to monitor disease progression and therapeutic response in large cohorts, as well as enable in the future the discovery and leveraging of microbial biomarkers for clinical research, screening tests, and diagnostics.

PI_NAMEs: TULLY, BENJAMIN  (contact)

PROGRAM_OFFICER_NAME: MCNEALY, TAMARA L

PROJECT_TERMS: Archaea;Bacteria;Bioinformatics;Biological Assay;Biological Markers;Biological Sciences;biomarker discovery;Cheek structure;Clinical;clinical diagnostics;clinical implementation;Clinical Research;cohort;Complex;Computer software;consumer product;cost;cost effective;cross reactivity;Data Set;Databases;Dental;Dental caries;design;Detection;Development;Diagnostic;diagnostic platform;Digit structure;Disease;disease phenotype;Disease Progression;Etiology;Evolution;Future;Generations;Genome;Genomic DNA;Genomics;Gingiva;Goals;Human;Human Microbiome;in silico;In Vitro;Industry;Infrastructure;innovation;insight;Knowledge;Longitudinal Studies;Los Angeles;member;metagenome;metagenomic sequencing;Metagenomics;Methodology;Methods;Microbe;microbial;microbiome;microorganism;Molecular;Monitor;next generation sequencing;novel;Oral;Oral cavity;Oral health;oral microbiome;oral pathogen;Output;Patients;Periodontal Diseases;Phase;Play;Process;Reaction;Research;Research Personnel;Risk;Role;Saliva;Sampling;Sampling Studies;scale up;screening;Sensitivity and Specificity;sequencing platform;Shotguns;Signal Transduction;Small Business Innovation Research Grant;Specificity;success;Techniques;Technology;technology platform;Testing;Time;Tongue;tool;treatment response;Validation;Variant;Work

PROJECT_TITLE: A Comprehensive qPCR-Based Oral Microbiome Profiling Platform for Research and Discovery

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MSOS-D (10)]


ORG_CITY: IOWA CITY

ORG_NAME: IOWA CITY VA MEDICAL CENTER

ORG_STATE: IA

PHR: Uncontrolled diabetes and aging both decrease muscle strength in veterans leading to impaired recovery from illness or surgery, and can even lead to early mortality. Diabetes and aging are associated with poor energy production in muscle mitochondria, the cellular powerhouses. Our previous work in mouse models showed that uncontrolled diabetes or aging causes muscle atrophy and mitochondrial dysfunction that depends on FoxO transcription factors. Our preliminary data shows FoxOs interact with Sin3a proteins to decreased mitochondrial genes and may be the cause of the mitochondrial problems and muscle fatigue in these conditions. The goal of this project is to see how these FoxO-Sin3 interactions control mitochondrial function, which will help us better understand the connections between diabetes, aging, and muscle weakness that contribute to disability in our Veteran population.

PI_NAMEs: O'NEILL, BRIAN TIMOTHY (contact)

PROJECT_TERMS: Age;age related;age related changes;aged;Aging;aging related;Atrophic;Binding;Bioenergetics;Biotin;carcinogenicity;Cell Nucleus;ChIP-on-chip;ChIP-seq;Complex;Contralateral;Data;Defect;Diabetes Mellitus;diabetic;Diabetic mouse;disability;experimental study;Fatigue;FOXO1A gene;FOXO3A gene;Gastrocnemius Muscle;Gene Expression;General Population;Genes;genetic corepressor;Genetic Transcription;glycemic control;Goals;Human;IGF1R gene;Immunoprecipitation;Impairment;improved;innovation;insight;Insulin;Insulin deficiency;Insulin Receptor;Insulin-Dependent Diabetes Mellitus;knock-down;Knock-out;Label;Lead;Liver;Malignant Neoplasms;Measures;Mediating;Messenger RNA;Metabolic;military veteran;Mitochondria;mitochondrial dysfunction;mitochondrial messenger RNA;mitochondrial metabolism;Modeling;Molecular;Molecular Target;Morphology;mortality;mouse model;Mus;Muscle;muscle aging;Muscle Fatigue;Muscle function;Muscle Mitochondria;muscle strength;Muscle Weakness;Muscular Atrophy;Myopathy;Neuropathy;Non-Insulin-Dependent Diabetes Mellitus;Nuclear;old mice;older patient;Operative Surgical Procedures;overexpression;Oxidative Phosphorylation;Ozone;Pathway interactions;Patients;preservation;prevent;Production;promoter;protein degradation;Proteins;Recovery;reduced muscle strength;Reporting;Repression;Role;Signal Transduction;Sin3A protein;Streptavidin;Streptozocin;Streptozocin Diabetes;System;Testing;Tissues;tool;transcription factor;Transcriptional Regulation;transcriptome sequencing;Up-Regulation;Veterans;Work

PROJECT_TITLE: Roles of FoxO interactions in diabetic and age-related muscle disease

STUDY_SECTION_NAME: Special Emphasis Panel[ZRD1 ENDA-L (01)]


ORG_CITY: TAMPA

ORG_NAME: UNIVERSITY OF SOUTH FLORIDA

ORG_STATE: FL

PHR: Narrative Dysregulation of calcium handling is common in cardiac arrhythmias and heart failure. There are millions of Americans living with heart failure and/or cardiac arrhythmias caused by electrical or mechanical abnormalities in the heart. Proposed studies in this project may lead to development novel therapeutics to treat patients with heart failure and/or cardiac arrhythmias.

PI_NAMEs: SONG, KUNHUA  (contact);VONDRISKA, THOMAS M.

PROGRAM_OFFICER_NAME: SCHWARTZ, LISA

PROJECT_TERMS: Address;Agreement;Alternative Splicing;American;Arginine;Arrhythmia;Binding;Biopsy;Ca(2+)-Transporting ATPase;Calcium;Cardiac;Cardiac Myocytes;Catecholaminergic Polymorphic Ventricular Tachycardia;Catecholamines;Cell Nucleus;Cells;Cessation of life;Chromatin;chromosome conformation capture;Coupling;Data;Defect;Development;Dihydropyridine Receptors;Down-Regulation;Exercise;exercise capacity;Exons;Functional disorder;Gene Expression;Gene Expression Regulation;Genes;Genetic Transcription;genome-wide;Heart;Heart Diseases;Heart failure;heart function;Homeostasis;Human;Impairment;Individual;Isoproterenol;Knock-out;Knockout Mice;Mechanics;Membrane;Membrane Potentials;Messenger RNA;Molecular;mRNA Precursor;Mus;Muscle Cells;Mutation;Myocardium;novel therapeutics;Nuclear;overexpression;Pathogenesis;Pathologic;Patients;Predisposition;premature;pressure;promoter;Promoter Regions;Protein Isoforms;recruit;Regulation;Research;response;RNA Splicing;Role;Ryanodine Receptor Calcium Release Channel;Sarcoplasmic Reticulum;Serine;Signal Transduction;Skeletal Muscle;Stress;sudden cardiac death;therapeutic target;Transcript;Transcriptional Regulation;triadin;Untranslated RNA

PROJECT_TITLE: Regulation of gene transcription and alternative splicing by a long non-coding RNA

STUDY_SECTION: MPPA

STUDY_SECTION_NAME: Integrative Myocardial Physiology/Pathophysiology A Study Section [MPPA]


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Cancer Genomics;Clinical Research;Genetics;Human Genome;Neurosciences;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

ORG_CITY: JACKSONVILLE

ORG_NAME: MAYO CLINIC  JACKSONVILLE

PHR: Glioblastoma Multiforme (GBM) is the most common and aggressive tumor in the brain. Among GBMs, those that are located near the brain lateral ventricles (LV) are the ones with the worst prognosis. Here we will investigate the specific mechanisms activated in brain tumors responsible for their increased malignancy in response to the LV.

PI_NAMEs: GUERRERO-CAZARES, HUGO  (contact)

PROGRAM_OFFICER_NAME: KOTLIAROVA, SVETLANA

PROJECT_TERMS: Adult;Amino Acids;Animal Model;Area;ATAC-seq;Automobile Driving;Back;Biopsy;Brain Neoplasms;Cathepsins B;Cell Communication;Cells;Cerebral Dominance;chemotherapy;Clinical;Coculture Techniques;Combined Modality Therapy;Data;differential expression;Distal;Distant;Excision;Exhibits;experimental study;Exposure to;gain of function;Glioblastoma;Goals;Human;Image Guided Biopsy;improved;In Vitro;in vivo;Infiltration;interest;Invaded;Label;lateral ventricle;Link;Location;loss of function;Maintenance;Malignant - descriptor;Malignant Neoplasms;Mammals;Maps;Methods;migration;multiple omics;neoplastic;neoplastic cell;nerve stem cell;Neurons;new therapeutic target;novel;Operative Surgical Procedures;Outcome;overexpression;Pathway interactions;Patient-Focused Outcomes;Patients;pluripotency;Population;Primary Brain Neoplasms;Prognosis;Proliferating;Property;Proteins;Proteome;Proteomics;Radiation therapy;Recurrence;response;Rodent;Role;Sampling;self-renewal;Series;Signal Induction;Signal Transduction;single nucleus RNA-sequencing;subventricular zone;Survival Rate;System;Testing;Therapeutic;Therapeutic Effect;therapeutic target;therapy resistant;trafficking;transcriptome;transcriptome sequencing;transcriptomics;treatment strategy;tumor;tumor growth;tumor initiation;tumor microenvironment;Tumor Promotion;Undifferentiated;With laterality

PROJECT_TITLE: TARGETING SIGNALING BETWEEN GLIOBLASTOMA AND THE SUBVENTRICULAR ZONE NICHE

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CN-V (03)]


ORG_CITY: BALTIMORE

ORG_NAME: UNIVERSITY OF MARYLAND BALTIMORE

ORG_STATE: MD

PHR: PROJECT NARRATIVE Elucidation of the molecular mechanisms underlying viral receptor usage alteration is critical for understanding viral pathogenesis, transmissibility, zoonotic potential, as well as for the development of therapeutic and preventative strategies. This application aims to test a potentially paradigm-shifting concept that viral entry pathway alteration can function as an evolutionary mechanism of immune evasion by elucidating the molecular mechanisms of HIV coreceptor switch. The proposed work is expected to resolve a long-standing question in the HIV field which has direct implications for HIV pathogenesis, therapeutics and functional cure, and has the potential to open a new research area aiming to understand the molecular mechanisms of viral entry pathway evolution under host immune defense.

PI_NAMEs: SONG, HONGSHUO  (contact)

PROGRAM_OFFICER_NAME: REFSLAND, ERIC WILLIAM

PROJECT_TERMS: Acceleration;Acquired Immunodeficiency Syndrome;Acute;acute infection;Africa;Area;Autologous;Biological;CCR5 gene;CD4 Positive T Lymphocytes;Cells;Cellular Tropism;Co-Receptor Switch;cohort;Coin;Coronavirus;cross-species transmission;CXCR4 gene;Data;Disease Progression;driver mutation;driving force;Epitopes;Evolution;fitness;flexibility;Goals;Hemostatic function;HIV;HIV Infections;Immune;Immune Evasion;immune reconstitution;Impairment;in vivo;influenzavirus;Integration Host Factors;Knowledge;Mediating;Memory;Memory B-Lymphocyte;Modeling;Molecular;Monoclonal Antibodies;Mutation;neutralizing antibody;novel;Participant;Pathogenesis;Pathogenicity;Pathway interactions;Phenotype;Preparation;pressure;Prevention strategy;Process;receptor;receptor binding;reconstitution;Research;Role;Sampling;Specificity;Testing;text searching;Thailand;Therapeutic;therapeutic development;Time;tissue tropism;transmission process;Tropism;Vaccine Design;Variant;Viral;Viral Genome;Viral Pathogenesis;virology;Virus;Virus Diseases;Virus Receptors;Work;Zoonoses

PROJECT_TITLE: Escape by Shifting: Viral Entry Tropism Shift as an Evolutionary Mechanism of Immune Evasion

STUDY_SECTION: HVCD

STUDY_SECTION_NAME: HIV Molecular Virology, Cell Biology, and Drug Development Study Section[HVCD]


ADMINISTERING_IC: EY

IC_NAME: NATIONAL EYE INSTITUTE

NIH_SPENDING_CATS: Diabetes;Eye Disease and Disorders of Vision;Neurodegenerative;Neurosciences;Prevention

ORG_CITY: MONTROSE

ORG_NAME: HILLHURST BIOPHARMACEUTICALS, INC.

PHR: PROJECT NARRATIVE This proposal is intended to support critical translational research evaluating whether HBI-002, an oral carbon monoxide therapeutic, can improve outcomes in translationally relevant animal models of diabetic retinopathy. If successful, the project will provide critical translational data for advancing the development of HBI-002 in diabetic retinopathy into the clinic, testing a promising therapeutic that could significantly improve the quality of life for those suffering from DR and ultimately reduce the societal burden of blindness caused by diabetes.

PI_NAMEs: GOMPERTS, EDWARD  (contact);JADEJA, RAVIRAJSINH ;MARTIN, PAMELA M

PROGRAM_OFFICER_NAME: LEE, PAEK-GYU

PROJECT_TERMS: Acute Respiratory Distress Syndrome;Adult;Advanced Development;Affect;Age;Air;Animal Model;Autopsy;Background Diabetic Retinopathy;Basic Science;bevacizumab;Binding;Biochemical;Blindness;Blood Glucose;Blood Vessels;Carbon Monoxide;Carboxyhemoglobin;Characteristics;Chronic;Clinic;Clinical;clinical implementation;Clinical Management;Clinical Research;Clinical Trials;Complications of Diabetes Mellitus;Coupled;Cytoprotection;Data;Data Analyses;db/db mouse;design;Development;Diabetes Mellitus;Diabetic mouse;Diabetic Retinopathy;Disease;Dose;Double-Blind Method;Drug Kinetics;efficacy evaluation;Elderly;Electrophysiology (science);Endothelial Cells;Ensure;Event;experience;Exposure to;Extravasation;Feedback;Fibrosis;follow-up;Functional disorder;Future;Gases;Gender;Genetic;glycemic control;Goals;Grant;Health;Hemoglobin;Hepatic;human model;Hyperglycemia;Hypoxia;improved;improved outcome;in vivo imaging;Inflammation;Inhalation;innovative technologies;Investigational Drugs;Ischemia;Kidney;Literature;manufacture;Measures;Modality;Modeling;Molecular;Monitor;Mus;neovascular;Nerve Degeneration;neurovascular;novel;Obesity;Ophthalmology;Oral;Oral Administration;Oxidative Stress;Oxygen;Pathogenicity;Pathologic;Pathologic Neovascularization;Patients;Persons;Pharmaceutical Preparations;Phase;phase 1 study;Phase I Clinical Trials;Phase II Clinical Trials;Phenotype;placebo controlled study;placebo group;postnatal;pre-clinical;pre-Investigational New Drug meeting;preclinical efficacy;preclinical study;Preparation;preservation;prevent;Prevention;Prodrugs;Property;Protocols documentation;Quality of life;Randomized;Recommendation;Regimen;Reperfusion Injury;response;Retina;Retinal Diseases;retinal imaging;retinal ischemia;Retinal Neovascularization;Risk;Route;Safety;safety testing;Small Business Innovation Research Grant;Small Business Technology Transfer Research;Streptozocin;Streptozocin Diabetes;Subarachnoid Hemorrhage;Testing;Therapeutic;Therapeutic Intervention;Time;Toxic effect;Toxicology;Translational Research;Treatment Efficacy;Vascular Endothelial Growth Factors;vascular injury;Virulence Factors;Visual Acuity;Weight

PROJECT_TITLE: HBI-002 to Treat Diabetic Retinopathy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-M (12)]


ED_INST_TYPE: SCHOOLS OF SOCIAL WELFARE/WORK

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

NIH_SPENDING_CATS: Drug Abuse (NIDA only);HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Social Determinants of Health;Substance Misuse

ORG_DEPT: OTHER HEALTH PROFESSIONS

ORG_NAME: COLUMBIA UNIV NEW YORK MORNINGSIDE

PHR: PROJECT NARRATIVE  This T32 trains pre- and post-doctoral scholars with diverse experiences from across the U.S., producing a well-trained generation of scientists who will be equipped to address some of the most pressing and/or entrenched problems affecting our country: HIV, substance use, and criminal legal system involvement. The forthcoming cycle will accelerate the implementation of high impact, science-based programs through a focus on implementation science, community engagement, and data science, altogether reducing health disparities and improving the health, well-being, and livelihoods of individuals, families, and communities highly impacted by the criminal legal system.

PI_NAMEs: EL-BASSEL, NABILA  (contact);METSCH, LISA R

PROGRAM_OFFICER_NAME: HIGHSMITH, KEISHER S

PROJECT_TERMS: Criminal Justice;HIV;substance use;System;Training Programs

PROJECT_TITLE: Training Program on HIV and Substance Use in the Criminal Justice System

STUDY_SECTION_NAME: Special Emphasis Panel[ZDA1 MXS-T (J1)]


ADMINISTERING_IC: MD

IC_NAME: NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES

NIH_SPENDING_CATS: Cancer;Climate-Related Exposures and Conditions;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Prevention;Skin Cancer;Social Determinants of Health

ORG_CITY: WILMINGTON

ORG_NAME: OLIPHA INC

ORG_STATE: DE

PHR: Project Narrative Due to bias in the sunscreen industry, there is unequal application of sunscreen in light and dark-skinned communities and ultimately this has helped result in a much higher mortality rate for dark-skinned individuals who develop melanoma. As an additional deterrent, most sunscreen products are made of physical blockers that make darker skins appear ashy, and sunscreens that don’t are typically chemical based where there is considerable concern around the safety of these chemicals both for human health and the health of natural environments. We are developing a physical sunscreen based on the naturally occurring, non-toxic, biodegradable microbial polyester poly-beta-hydroxybutyrate that is far less whitening than physical sunscreens on the market today.

PI_NAMEs: CAL, ANDREW  (contact)

PROGRAM_OFFICER_NAME: LAI, GABRIEL Y

PROJECT_TERMS: Address;Adoption;Affect;Appearance;Bacillus megaterium;beta-Hydroxybutyrate;biomaterial compatibility;Blood Circulation;Carbon;chemical safety;Chemicals;Color;Communities;crystallinity;Cytoplasmic Granules;Darkness;Death Rate;design;Development;disparity elimination;DNA Damage;Dryness;Environment;Environmental Impact;Environmental Risk Factor;Esthetics;Ethnic Origin;Evaluation;Fatality rate;Fermentation;Formulation;Health;Human;human subject;Incidence;Individual;Industry;innovation;Light;light transmission;marine;Marketing;Measurement;Measures;Melanins;Melanoma;microbial;Minerals;Nature;particle;Particle Size;Patients;people of color;Persons;Phase;phase 2 study;Polyesters;Powder dose form;Production;recruit;Research;Risk;Sensory;Skin;Skin Cancer;skin color;Structure;Sunscreening Agents;Temperature;titanium dioxide;transmission process;ultraviolet;Ultraviolet Rays;United States;UV induced DNA damage;UV protection;Vertebrates;Visible Radiation;Work

PROJECT_TITLE: A Biobased Biodegradable Sunscreen that is Safe, Removes Environmental Impact, is Inclusive of all Skin Tones, and is for the Purpose of Eliminating Disparities in Melanoma Mortality Rates

STUDY_SECTION_NAME: Special Emphasis Panel[ZMD1 JT (J1)]


ORG_CITY: DALLAS

ORG_NAME: UT SOUTHWESTERN MEDICAL CENTER

ORG_STATE: TX

PHR: Project Narrative The proposed work will determine neuron-specific mechanisms that regulate innate immune responses in the brain. Our preliminary data show that asyn expression supports type 1 interferon signaling in neurons. The proposed work will define the mechanism of asyn-dependent interferon signaling in neurons and provide new mechanistic insight into the interactions between innate immunity and specific mutations in asyn that are known to be important in the development of Parkinson’s Disease. The proposed studies will define fundamental mechanisms of innate immunity in the brain.

PI_NAMEs: BECKHAM, JOHN DAVID (contact)

PROGRAM_OFFICER_NAME: SULLIVAN, LUIS FLANAGAN

PROJECT_TERMS: Acute;alpha synuclein;Autoimmune Diseases;Binding;Biological Assay;Brain;Cell Separation;Cells;Central Nervous System;Central Nervous System Diseases;Cerebrovascular Disorders;Clustered Regularly Interspaced Short Palindromic Repeats;Coculture Techniques;Data;Development;dopaminergic neuron;Event;Exhibits;Gene Expression;Gene Knock-Out Model;Gene Mutation;Genes;Goals;Growth;Homeostasis;Human;human disease;Immune;Immune response;Impairment;in vivo;induced pluripotent stem cell;Infection;Infiltration;Innate Immune Response;insight;Interferon Type II;Interferons;Knock-out;Knockout Mice;Link;Lymphocyte;Malignant Neoplasms;Mediating;Microfluidic Microchips;Microglia;Mus;Mutation;Natural Immunity;Nerve Degeneration;Nervous System;Nervous System Physiology;nestin protein;Neurodegenerative Disorders;neuroimmunology;neuroinflammation;neuronal cell body;Neurons;novel;Nuclear;Organism;Parkinson Disease;Pathogenesis;Pathway interactions;Physiological;Poly I-C;Production;Proteins;receptor;Regulation;Research;response;Role;Signal Transduction;Signaling Protein;Site;STAT protein;STAT2 gene;synuclein;System;T cell infiltration;T cell response;T-Cell Activation;T-Lymphocyte;Testing;Time;TRAMP protein;transcriptome;Traumatic Brain Injury;TRIM25 gene;Venezuelan Equine Encephalitis Virus;Vesicle;vesicle transport;Viral;Virus;Virus Diseases;Work

PROJECT_TITLE: Determining the mechanism of alpha-synuclein dependent innate immune responses in the brain

STUDY_SECTION: CDIN

STUDY_SECTION_NAME: Chronic Dysfunction and Integrative Neurodegeneration Study Section[CDIN]


NIH_SPENDING_CATS: Biotechnology;HIV/AIDS;Immunization;Infectious Diseases;Pediatric;Pediatric - AIDS;Prevention;Vaccine Related;Vaccine Related - AIDS

ORG_CITY: DURHAM

ORG_DEPT: SURGERY

ORG_NAME: DUKE UNIVERSITY

PHR: Narrative statement: A key goal of a HIV-1 vaccine is to induce HIV-1 envelope (env)-reactive broadly neutralizing antibodies (bnAbs) that can neutralize geographically-diverse or heterologous HIV-1 strains. Understanding the cellular and molecular mechanisms of HIV-1 Env bnAb induction following neonatal SHIV infection in young macaques will improve our understanding of pediatric HIV-1 immunity, and inform vaccine strategies to induce bnAbs in infants and children prior to sexual debut.

PI_NAMEs: WILLIAMS, WILTON B (contact)

PROGRAM_OFFICER_NAME: SINGH, ANJALI

PROJECT_TERMS: Adult;Animals;Antigens;Autologous;Award;B-Cell Activation;B-Cell Antigen Receptor;B-Cell Development;B-Lymphocytes;Biological Assay;Biological Markers;Blood;candidate identification;Cell Maturation;Cells;Characteristics;Child;Childhood;Computing Methodologies;deep sequencing;design;Development;Dissection;Event;Evolution;Flow Cytometry;Frequencies;Generations;Genome;Geography;global health;Goals;Grant;Growth;Health Priorities;HIV-1;HIV-1 vaccine;Human;Immune;Immunity;Immunogenetics;Immunoglobulin Genes;Immunologics;improved;Infant;innovation;Kinetics;Knowledge;Life;Macaca;Macaca mulatta;Modeling;Molecular;Mutation;Nature;Neonatal;neonatal immunity;neonatal infection;neonate;neutralizing antibody;next generation;novel;Pathway interactions;Pattern;pediatric human immunodeficiency virus;permissiveness;Plasma;Population;pressure;prevent;Research Design;response;Sampling;sexual debut;simian human immunodeficiency virus;Site;Specificity;Structure of germinal center of lymph node;Testing;Time;Tissues;transcriptome sequencing;transcriptomics;Vaccine Design;vaccine development;vaccine strategy;Vaccines;Viral;Viral Load result;Virus Diseases

PROJECT_TITLE: Neonatal Immunity to novel TF SHIVs

STUDY_SECTION: HIVD

STUDY_SECTION_NAME: HIV Immunopathogenesis and Vaccine Development Study Section[HIVD]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Biotechnology;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Dementia;Neurodegenerative;Neurosciences

ORG_CITY: New Haven

ORG_NAME: ALLYX THERAPEUTICS INC.

ORG_STATE: CT

PHR: PUBLIC HEALTH NARRATIVE Today, no conclusive disease-modifying therapies for AD are available. Synapse loss in AD brain has been tightly correlated with symptoms and is triggered initially by amyloid beta peptide accumulation. We have mapped a pathway from amyloid-β oligomers to synapse loss. Central to this pathway is the transmembrane receptor mGluR5, a metabotropic glutamate receptor, which when complexed with cellular prion protein triggers synaptic dysfunction and recruits immune mediators for microglial mediated pruning. We have developed an orally bioavailable small molecule drug which selectively blocks AD dependent damage while preserving normal physiologic signaling through mGluR5. Here, we aim to develop this compound to slow, halt or partially reverse AD progression both in the MCI state and in mild dementia.

PI_NAMEs: SIEGERT, TIMOTHY R (contact)

PROGRAM_OFFICER_NAME: WILLIAMS, BENFEARD LEECHELLE

PROJECT_TERMS: abeta oligomer;Address;Affect;Alzheimer's Disease;Alzheimer's disease brain;Alzheimer's disease model;Alzheimer's disease patient;Alzheimer's disease therapy;Amyloid beta-Protein;Benchmarking;Binding;Biological;Biological Availability;Biological Response Modifiers;Biotechnology;Caffeine;capsule;Caregivers;Cause of Death;Censuses;Clinical;clinical efficacy;Clinical Research;clinical research site;Cognition;commercial application;commercialization;comorbidity;Complex;CYP1A2 gene;CYP2D6 gene;CYP3A4 gene;Data;Dementia;dementia burden;dementia care;density;Development;Dextromethorphan;Disease;Disease Progression;Dose;Drug Interactions;Drug Kinetics;drug metabolism;Formulation;Functional disorder;Genetic;genome wide association study;Goals;Hippocampus;Hour;Human;human subject;Impaired cognition;improved;Individual;Intravenous;Knock-out;Knowledge;Label;Licensing;manufacture;manufacturing run;Maps;Measurement;Mediating;meetings;Membrane;Memory;Metabolism;metabotropic glutamate receptor 5;Metabotropic Glutamate Receptors;method development;Methods;Midazolam;mild cognitive impairment;Mus;Neurodegenerative Disorders;novel;novel therapeutics;Nuclear Magnetic Resonance;older adult;Onset of illness;operation;Oral;Outcome;Pathology;Pathway interactions;patient-level barriers;Patients;Performance;Pharmaceutical Preparations;Pharmacologic Substance;Pharmacotherapy;Phase;phase 2 study;Phase II Clinical Trials;Phosphotransferases;Physiological;Plasma;pre-clinical;preclinical development;preservation;prevent;Price;PrP;PTK2B gene;Public Health;Quality of life;receptor;recruit;research clinical testing;Risk;Rodent;Route;Safety;Sales;Sample Size;Sampling;Signal Transduction;Small Business Innovation Research Grant;small molecule;Specific qualifier value;Structure;Symptoms;Synapses;System;tau Proteins;technological innovation;Therapeutic;therapeutic target;Time;Toxic effect;Treatment Protocols;Universities;Urine

PROJECT_TITLE: Clinical evaluation of BMS-984923 metabolism.

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-B (19)]


NIH_SPENDING_CATS: Biotechnology;Brain Disorders;Genetics;Intellectual and Developmental Disabilities (IDD);Neurosciences;Orphan Drug;Pediatric;Rare Diseases

ORG_CITY: EDISON

ORG_NAME: COURAGENE, INC.

ORG_STATE: NJ

PHR: Angelman syndrome (AS) is a severe neurodevelopmental disorder without effective treatment. This research project focuses on the development of a novel nonviral delivery technology for genome editing-based therapy. It will result in a chemically modified ribonucleoprotein (cRNP) complexed with Cas9 protein and gRNA for delivery of CRISPR mediated gene editing to the brain, which can significantly enhance the clinical treatment for patients with AS.

PI_NAMEs: XIE, YING  (contact)

PROJECT_TERMS: Acceleration;Angelman Syndrome;Anti-sense RNA;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;base editing;Biodistribution;Brain;Cells;Chemical Engineering;chemical safety;chemical synthesis;Chemicals;Cholesterol;Clinical;clinical translation;Clinical Treatment;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Collection;Complex;Data;density;Development;Developmental Delay Disorders;Disease;DNA;Dose;effective therapy;efficacy study;Evaluation;Event;Fibroblasts;Formulation;Foundations;Genes;genome editing;Guide RNA;Human Genome;human induced pluripotent stem cells;Immune response;immunogenicity;Impairment;improved;In Vitro;Independent Living;Individual;innovation;Intellectual functioning disability;Intrathecal Injections;Mediating;Mus;Nature;neurobehavioral;Neurodevelopmental Disorder;neurogenetics;neuroinflammation;Neurons;novel;Patients;Penetration;Phase;Phenotype;Polyethylene Glycols;Proteins;Reporter;Research Project Grants;response;Ribonucleoproteins;Safety;safety study;Seizures;Solid;Speech;Surface;symptom management;systemic toxicity;Technology;Testing;Therapeutic;therapeutic genome editing;Tissues;Toxic effect;Treatment Efficacy;UBE3A gene;Untranslated RNA;vector genome;Work

PROJECT_TITLE: Engineering Chemically Modified RNPs for Effective Treatment of Angelman Syndrome

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-S (14)]


ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

ORG_CITY: ATLANTA

ORG_DEPT: ENGINEERING (ALL TYPES)

ORG_NAME: GEORGIA INSTITUTE OF TECHNOLOGY

ORG_STATE: GA

PHR: Cell signaling therapies target lung cancer patients with a well-defined mutation in the common cellular signaling, but almost all patients ultimately develop acquired resistance to this targeted therapy due to the emergence of clones with genomic alterations that confer survival advantage and their tumors' molecular heterogeneity. The proposed research will build a molecular screening platform for imaging signaling protein interactions in human cell cultures and tissues from physiologically relevant cancer models using multiplexed measurement techniques to record spatial signaling interactome patterning of subcellular and cellular distributions in patients' biopsies with gene mutations. The biological lung cancer model system will demonstrate how subcellular wiring of signaling factors provides subset patients that can be used for personalized and precision signaling therapies in lung cancers.

PI_NAMEs: COSKUN, AHMET F. (contact)

PROGRAM_OFFICER_NAME: MCKEE, TAWNYA C

PROJECT_TERMS: Aftercare;Apoptosis;Bioinformatics;Biological;Biological Assay;Biological Models;Biopsy;cancer cell;Cancer Model;Cancer Patient;cancer therapy;Cell Culture Techniques;Cell Line;Cell Nucleus;Cells;Cessation of life;Chemistry;Clinical;Clinical Trials;combinatorial;Combined Modality Therapy;Cytometry;Cytosol;Data;design;Disease;Disease Progression;DNA Sequence Alteration;drug-sensitive;EGFR gene;Endoplasmic Reticulum;Epidermal Growth Factor Receptor;Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor;Event;Exposure to;Flow Cytometry;Gene Expression Profiling;Gene Mutation;Goals;Growth;Heterogeneity;Human;Human Cell Line;human tissue;Image;imaging modality;imaging platform;Immunofluorescence Immunologic;improved;In Situ;In Vitro;in vitro Assay;in vivo;in vivo Model;Individual;inhibitor;innovation;insight;Intervention;Knowledge;Label;Ligation;Location;lung cancer cell;Mainstreaming;Malignant neoplasm of lung;Malignant Neoplasms;Maps;Measurement;Measures;MEKs;Methods;Mitochondria;Modeling;Molecular;Molecular Profiling;Mus;Mutation;Neighborhoods;Non-Small-Cell Lung Carcinoma;novel;operation;Organelles;Organizational Models;Outcome;Pathology;patient derived xenograft model;patient stratification;patient subsets;Patients;Pattern;Pharmaceutical Preparations;Pharmacotherapy;Physiological;Population;preclinical study;Progression-Free Survivals;Proliferating;protein protein interaction;Proteins;Publishing;ratiometric;rational design;reconstruction;Research;Resistance;resistance mechanism;Resolution;response;screening;Signal Transduction;Signaling Protein;single cell proteins;single-cell RNA sequencing;Slice;targeted treatment;Taxonomy;Techniques;Technology;Testing;tissue/cell culture;Tissues;tool;Treatment outcome;tumor;tumor heterogeneity;tumor progression;Western Blotting;Work;Xenograft Model;Xenograft procedure

PROJECT_TITLE: Spatial protein-protein interaction networks in situ by multiplexed proximity ligation

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 TCRB-D (M2)]


NIH_SPENDING_CATS: Clinical Research;Conditions Affecting the Embryonic and Fetal Periods;HIV/AIDS;Hematology;Infectious Diseases;Pediatric;Pediatric - AIDS;Perinatal Period - Conditions Originating in Perinatal Period;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Stem Cell Research - Umbilical Cord Blood/ Placenta;Stem Cell Research - Umbilical Cord Blood/ Placenta - Human

PHR: Project Narrative: An estimated 1.3 million HIV-exposed, uninfected (HEU) children are born annually to mothers-living with HIV. A vast majority of HEU children have higher risk for opportunistic infections within the first 6 months of life, most likely due to hematopoietic & immune defects. A deeper understanding on HIV-induced pathophysiological consequences on hematopoiesis on HEU children may define potentially new targets for treating hematologic disorders and immune dysfunctions caused by in-utero exposure of HIV.

PI_NAMEs: CAIRO, CRISTIANA ;RATHINAM, CHOZHA VENDAN (contact)

PROGRAM_OFFICER_NAME: MILLER, JUDITH A

PROJECT_TERMS: Affect;Anemia;antiretroviral therapy;Bacteremia;Biochemical;Biophysics;Blood;Bone Marrow;Bone marrow failure;CD8-Positive T-Lymphocytes;Cell Lineage;Cell Maintenance;Cells;Cellular biology;Child;Chronic;clinically relevant;cytokine;Cytometry;Data;Death Rate;Defect;Dendritic Cells;design;differentiation in vitro;effective therapy;Engraftment;Event;Exhibits;Flow Cytometry;Frequencies;Genetic;Goals;Hematological Disease;Hematopathology;Hematopoiesis;Hematopoietic;hematopoietic differentiation;Hematopoietic stem cells;high risk;HIV;HIV Infections;HIV-1;HIV-exposed uninfected infant;Human;humanized mouse;Immune;immune function;Immune response;Immune System Diseases;Immunity;Impairment;in utero;In Vitro;Individual;Infant;Infection;Inflammation;Inflammation Mediators;Inflammatory;insight;Investigation;Knowledge;Life;Link;Lymphoid;Macrophage;Maintenance;Maternal Exposure;microbial;Molecular;monocyte;Mononuclear;Morbidity - disease rate;mortality;Mothers;mouse model;Myelogenous;Myeloid Cells;Myeloid Progenitor Cells;Natural Killer Cells;Newborn Infant;novel;Opportunistic Infections;Outcome;Pancytopenia;Pathway interactions;Patients;Peripheral;Persons;Physiological;Predisposition;prenatal exposure;progenitor;Proteomics;Research;Respiratory Tract Infections;self-renewal;Signal Transduction;Source;stem cell function;T-Lymphocyte;Testing;Therapeutic;Thrombocytopenia;transcription factor;Umbilical Cord Blood;Virus;Xenograft procedure

PROJECT_TITLE: Deciphering hematopoietic stem cell defects in HIV exposed, uninfected infants born to ART-treated mothers

STUDY_SECTION: HCCS

STUDY_SECTION_NAME: HIV Comorbidities and Clinical Studies Study Section[HCCS]


ADMINISTERING_IC: HD

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Genetics;Human Genome;Stem Cell Research;Stem Cell Research - Embryonic - Non-Human;Women's Health Research

ORG_CITY: ANN ARBOR

ORG_DEPT: GENETICS

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PHR: Narrative This proposal is relevant to public health because it seeks to understand how females with two X chromosomes and males with a single X chromosome equalize gene expression from the X chromosome. The proposed research will test the contribution of X-chromosome inactivation, which silences genes on one of the two X chromosomes in females, as well as novel evolutionarily-ancient mechanisms in equalizing X chromosomal gene expression between the sexes. The proposal is relevant to the part of the NIH mission that seeks to advance fundamental knowledge about the nature of living systems.

PI_NAMEs: KALANTRY, SUNDEEP  (contact)

PROGRAM_OFFICER_NAME: STEIN, KATHRYN K

PROJECT_TERMS: Adult;Alleles;Bioinformatics;Biological Models;Biology;Breeding;Candidate Disease Gene;Cells;Chromatin;chromatin modification;Chromosomes;Code;Development;Dissection;Dosage Compensation (Genetics);Dosage Forms;Embryo;embryonic stem cell;Epiblast;Equilibrium;Evolution;experimental study;Female;Gene Expression;Gene Expression Profile;Gene Silencing;Genes;Genetic Recombination;Goals;Inequality;innovation;insight;Knowledge;Link;male;Mammals;Mission;Modeling;Molecular;mouse model;Mus;Nature;nerve stem cell;novel;Organism;Placenta;Ploidies;prevent;Proteins;Public Health;recruit;Research;RNA;RNA Interference;Series;sex;Sex Chromosomes;Sex Differences;Sex Differentiation;single molecule;Techniques;Testing;Tissues;transcriptome sequencing;transcriptomics;United States National Institutes of Health;Untranslated RNA;Work;X Chromosome;X Inactivation;Y Chromosome

PROJECT_TITLE: Evolution of Mammalian Sex Chromosome Dosage Compensation

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 BTC-Q (70)]


ORG_CITY: Aurora

ORG_NAME: UNIVERSITY OF COLORADO DENVER

PHR: PROJECT NARRATIVE Antibodies are extremely diverse, making it highly improbable for any two people to express the same antibody gene configuration, but we identified a set of 'public' antibodies in the human gut that were biased to either persons living with HIV-1 or to HIV-1-uninfected individuals. We suspect that these antibodies interact with bacterial communities in the gut called the microbiome, and if so, these interactions may inform public antibody-based therapies to counteract chronic inflammation in HIV-1 infection and a wide range of medical conditions due to a 'leaky gut'.

PI_NAMEs: SANTIAGO, MARIO LUIS (contact);WILSON, CARA C.

PROGRAM_OFFICER_NAME: SHANKAR, UDAY K

PROJECT_TERMS: Address;Age;Antibodies;Antibody Repertoire;Antibody Therapy;antigen binding;Antigenic Specificity;Antigens;antiretroviral therapy;B-Lymphocytes;Bacteria;bacterial community;Binding;Biological;Biology;Biopsy;Bone Diseases;Cardiovascular Diseases;CD4 Positive T Lymphocytes;Cell Death;Chronic;Circulation;Clinical Research;clinical translation;Clonal Expansion;cohort;Colon;comorbidity;cytokine;Data;Data Set;Defect;Disease;dysbiosis;Enterobacteriaceae;experimental study;Frequencies;Gastrointestinal Diseases;gastrointestinal epithelium;Gastrointestinal tract structure;Genes;germ free condition;Goals;gut homeostasis;gut microbes;gut microbiome;gut microbiota;Health;HIV-1;Homeostasis;Human;Hyperplasia;IgA Deficiency;Immune;immune activation;Immunoglobulin A;Immunoglobulin Genes;Immunoglobulin Somatic Hypermutation;Inbreeding;Individual;Infection;Inflammation;Inflammatory;Inflammatory Bowel Diseases;insight;Kidney Diseases;Knockout Mice;Knowledge;Lamina Propria;Leaky Gut;Ligands;Light;Link;Lymphocyte;lymphoid structures;Mediating;Medical;microbial;microbial composition;microbiome;microbiota;Modeling;mortality;Mucosal Immunity;Mucositis;Mucous Membrane;multidisciplinary;Mus;Nature;next generation sequencing;novel strategies;Pathway interactions;peripheral blood;Persons;Physiological;Plasma Cells;Polysaccharides;preservation;Production;Property;Recombinants;Recording of previous events;Reporting;Risk;Role;sex;Specificity;Syndrome;T-Cell Depletion;Testing;Therapeutic;virology

PROJECT_TITLE: The Public Mucosal Antibody Repertoire in HIV-1 Infection


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Chronic Pain;Disability Research;Neurodegenerative;Neurosciences;Pain Research;Peripheral Neuropathy;Physical Injury - Accidents and Adverse Effects;Regenerative Medicine;Rehabilitation;Transplantation

ORG_NAME: INSOMA BIO, INC.

ORG_STATE: NC

PHR: PROJECT NARRATIVE Peripheral nerve injuries impact over 20 million people in the US alone, resulting in nearly $150 billion in healthcare costs annually, and, despite repair using advanced microsurgical techniques, patients are often left with lifelong disability. This Phase 1 STTR proposal intends to develop an innovative injectable biomaterial scaffold—FractomerTM— to enhance peripheral nerve repair by addressing the unmet needs in current repair methods. If successful, this approach could significantly improve the well-being of millions of patients by reducing long-term disability and chronic pain.

PI_NAMEs: CHILKOTI, ASHUTOSH ;ROBERTS, STEFAN  (contact)

PROGRAM_OFFICER_NAME: GILCHRIST, FLOY ANNETTE

PROJECT_TERMS: Address;Affect;Allografting;Analysis of Variance;Animal Testing;Area;Autologous Transplantation;Axon;axonal sprouting;Biocompatible Materials;biocompatible scaffold;Biological;biomaterial compatibility;bioscaffold;Body Temperature;Cell Differentiation process;Cell-Matrix Junction;Cells;Chronic;chronic pain;Clinical;clinical application;clinical translation;Clinical Treatment;commercialization;Confocal Microscopy;Control Groups;crosslink;Distal;efficacy evaluation;efficacy testing;Elasticity;Elastin;Electrophysiology (science);experience;experimental group;Fibrin Tissue Adhesive;Formulation;Foundations;functional disability;gait examination;Goals;Health Care Costs;Histologic;improved;improved outcome;in vivo;indexing;Industry;Industry Standard;Infiltration;Inflammation;Inflammatory Response;Injectable;injury and repair;innovation;Isometric Exercise;Left;Length;Libraries;Lifelong disability;Liquid substance;Long term disability;manufacturing process;Marketing;Measurement;Measures;mechanical properties;Mechanics;Metabolic;Methods;Microsurgery;migration;mimetics;Modeling;Modulus;Molecular Weight;Morbidity - disease rate;Muscular Atrophy;Natural regeneration;neovascularization;Nerve;Nerve Regeneration;nerve repair;non-invasive imaging;Operating Rooms;Operative Surgical Procedures;Outcome;Patients;PECAM1 gene;Peripheral nerve injury;peripheral nerve regeneration;peripheral nerve repair;Personal Satisfaction;Persons;Phase;Phase Transition;Physiological;Placebos;polypeptide;Porosity;Pre-Clinical Model;Procedures;Property;Rattus;Recombinants;Recovery;repaired;scaffold;scale up;Schwann Cells;sciatic nerve injury;Small Business Technology Transfer Research;Solid;Stains;standard care;success;Surgeon;surgery outcome;Surgical sutures;Techniques;Temperature;Testing;Time;Tissues;Translations;treatment group;treatment strategy;ultrasound;Variant;Vascularization;Vertebral column;Viscosity;Walking

PROJECT_TITLE: Enhancing Peripheral Nerve Repair with an Injectable Recombinant Polypeptide Scaffold

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-H (13)]


ORG_CITY: CAMBRIDGE

ORG_NAME: BROAD INSTITUTE, INC.

PHR: Project Narrative Cells are the unit building blocks of tissues and organs, thus, to understand how tumors progress and develop in tissues and organs, it is important to understand where different types of healthy and tumor cells reside in the tissue. Here, we are developing new technologies that allows clinical scientists to simultaneously look at who cells are, via the genes they express, and where they reside across many different tumor types.

PI_NAMEs: CHEN, FEI  (contact)

PROGRAM_OFFICER_NAME: LI, JERRY

PROJECT_TERMS: Adoption;Affect;Antineoplastic Agents;Benchmarking;Biological Markers;cancer cell;cancer genomics;Cell Communication;Cell Nucleus;cell type;Cells;Chromatin;Chromosome abnormality;Clinical;Communities;Complex;computational pipelines;computer framework;Data;Development;Diagnostic;Disease Progression;disorder control;Dissociation;Ecosystem;Environment;Epigenetic Process;epigenomics;Equipment;Evolution;Fibroblasts;Future;Gene Expression;Gene Expression Profile;Genes;Genetic study;Genetic Transcription;Genetic Variation;Genome;genomic tools;Genomics;Growth;Heritability;Heterogeneity;Histologic;Human;Image;imaging modality;Immune;immune cell infiltrate;Immunologic Receptors;Immunotherapy;In Situ;Individual;innovation;invention;Malignant - descriptor;Malignant Neoplasms;Measurement;Measures;Methylation;Molecular;multimodality;multiple omics;Neoplasm Metastasis;neoplastic cell;new technology;Non-Malignant;novel;novel therapeutics;Organ;Pathology;personalized diagnostics;Phenotype;prognostic;Protocols documentation;Resistance;Resolution;response;Scientist;Signal Transduction;single cell genomics;single nucleus RNA-sequencing;Slide;Solid Neoplasm;Somatic Mutation;Specimen;Standardization;success;T cell infiltration;T-Cell Receptor;T-Lymphocyte;Technology;technology platform;Therapeutic;Time;Tissues;tool;Training;transcriptome;transcriptomics;Treatment Failure;treatment response;tumor;tumor growth;tumor heterogeneity;Tumor Immunity;tumor microenvironment;tumor progression;Validation;Variant;Work

PROJECT_TITLE: A platform for multi-modal single nucleus spatial genomics for molecular tumor analysis


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease Related Dementias (ADRD);Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Dementia;Lewy Body Dementia;Neurodegenerative;Neurosciences;Parkinson's Disease

ORG_CITY: WOODS HOLE

ORG_NAME: MARINE BIOLOGICAL LABORATORY

PHR: PROJECT NARRATIVE These studies on -synuclein are relevant to public health because they will provide mechanistic insight into the synapse-based mechanisms underlying cognitive deficits and dementia in Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and variants of Alzheimer’s disease (AD). These studies focused on -synuclein at synapses will significantly advance our knowledge of early stages of disease pathogenesis, which is complementary to studies on protein aggregation and neurotoxicity mechanisms. In addition, the proposed work will also provide critical knowledge on the interplay between -synuclein and synaptic mitochondria, thus impacting our understanding of PD and DLB disease pathogenesis, as well as other conditions where synapse function is compromised such as brain and spinal cord injury, neuromuscular disorders, and stroke.

PI_NAMEs: MORGAN, JENNIFER REBECCA (contact)

PROGRAM_OFFICER_NAME: SARRAF, SHIREEN AKHAVAN

PROJECT_TERMS: Acute;Affect;Agreement;Binding;Brain;Cognitive deficits;Dementia with Lewy Bodies;dimer;Disease;Endocytosis;experimental study;Functional disorder;Goals;Human;Impairment;improved;inhibitor;insight;Knowledge;Lampreys;Lewy Body Disease;Lewy Body Variant of Alzheimer's Disease;Link;Membrane;Mitochondria;Molecular;monomer;Neuromuscular Diseases;Neurons;neurotoxicity;parent project;Parkinson Disease;Parkinson's Dementia;Pathogenesis;Pathologic;Pathology;Post-Translational Protein Processing;Postbaccalaureate;prevent;protein aggregation;Public Health;spinal cord and brain injury;Stroke;Structure;Study models;Synapses;synaptic function;synaptic inhibition;Synaptic Vesicles;synuclein;therapy development;trafficking;Variant;Work

PROJECT_TITLE: Mechanisms of Synaptic Dysfunction in Parkinson's and Other Synuclein-Linked Diseases


NIH_SPENDING_CATS: Antimicrobial Resistance;Biodefense and Related Countermeasures;Bioengineering;Emerging Infectious Diseases;Infectious Diseases;Lung;Rare Diseases;Tuberculosis

ORG_CITY: Madison

ORG_NAME: SALUS DISCOVERY, LLC

ORG_STATE: WI

PHR: PROJECT NARRATIVE Point-of-care (POC) diagnostic testing is key to effective management of tuberculosis (TB), a disease that ranks second in global disease deaths behind COVID-19; however, progress is limited by inherent limitations of current testing methods. This project overcomes current limitations using a simple (3 step), cheap, and fast, assay for ultra-sensitive detection of TB at the POC. In Phase I we will perform assay optimization, prototype and test an ultrasonic lysis module to ensure assay robustness, and perform a small-scale pilot study of clinical sensitivity; And in Phase II we will finalize the 3STEP assay and consumable for an expanded clinical evaluation and subsequently perform that clinical evaluation in preparation for commercialization.

PI_NAMEs: WARRICK, JAY WYATT (contact)

PROGRAM_OFFICER_NAME: LACOURCIERE, KAREN A

PROJECT_TERMS: Address;aspirate;assay development;Benchmarking;Binding;biobank;Biological Assay;Budgets;Cause of Death;Cessation of life;Chemistry;Clinic;Clinical;Clinical Sensitivity;Closure by clamp;Collection;commercialization;Communities;Consultations;cost;COVID-19;Cytolysis;design;Detection;Development;Devices;Diagnostic Procedure;Diagnostic tests;Disease;DNA;Drug resistance;drug testing;Dryness;Ensure;Evaluation;Evaluation Studies;feasibility testing;Freeze Drying;Funding;Future;Health care facility;Infection;Injections;instrument;instrumentation;lateral flow assay;Learning;Liquid substance;lymph node biopsy;Manufacturer;Methods;Molds;Molecular;Mutation;Mycobacterium tuberculosis;novel;Oral;Oral Tuberculosis;Organism;Patients;Performance;Pharmacy facility;Phase;Pilot Projects;point of care;Point of Care Technology;point-of-care diagnostics;Polymorphism Analysis;Preparation;programs;prototype;Reaction;Reader;Readiness;Recommendation;research clinical testing;resistant strain;Rifampicin resistance;Sampling;school based health center;seal;Single Nucleotide Polymorphism;Small Business Innovation Research Grant;Specificity;Speed;Sputum;stability testing;Stomach;Swab;Technology;Testing;Time;Tongue;Tube;Tuberculosis;tuberculosis diagnostics;Ultrasonics;urgent care;Urine;Validation

PROJECT_TITLE: 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 DCAI-B (13)]


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD)

ORG_CITY: MILWAUKEE

ORG_NAME: 3D MOLECULAR DESIGNS

PHR: Project Narrative Harnessing Machine Learning & Object Detection for Automated Evaluation of Student-folded Protein Models The Harnessing Machine Learning & Object Detection for Automated Evaluation of Student-folded Protein Models will, in the long term, impact public health through improved bioscience education in secondary schools. This application will give students real-time feedback on their modeling of proteins in the physical world. As students build their physical models of proteins, they simultaneously build their conceptual understanding of proteins, the critical part of nearly all biological systems.

PI_NAMEs: HOELZER, MARK ;RYAN, HEATHER  (contact)

PROGRAM_OFFICER_NAME: FAUPEL-BADGER, JESSICA

PROJECT_TERMS: 3-Dimensional;alpha helix;Amino Acid Motifs;assessment application;Augmented Reality;beta pleated sheet;Bioinformatics;Biological Models;Biological Sciences;biological systems;Code;Computer software;Computer Vision Systems;Computers;Data;Data Collection;design;Detection;digital;digital applications;Digital Computers;digital media;Documentation;Education;Environment;Evaluation;feasibility research;feasibility testing;feature detection;Feedback;formative assessment;Goals;improved;innovation;Learning;Left;Libraries;Machine Learning;machine learning framework;Methods;model design;Modeling;Molecular;open source;outreach program;Phase;physical model;Problem Solving;protein folding;protein function;Protein Region;protein structure;Proteins;Public Health;Research;research and development;Running;Scanning;Science;science education;Secondary Schools;Self Correction;Shapes;skills;Structure;student training;Students;System;Techniques;Technology;TensorFlow;Testing;three-dimensional visualization;Time;tool;Training;Vertebral column;Video Recording;web-based tool;Zinc Fingers

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-M (56)]


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Emerging Infectious Diseases;Infectious Diseases;Lyme Disease;Prevention;Rare Diseases;Tickborne Diseases;Vector-Borne Diseases

ORG_CITY: Ridgefield

ORG_NAME: BIOPEPTIDES, INC.

PHR: Project Narrative: Babesiosis is a tick-transmitted disease that is a common coinfection with Lyme disease. There has been an exponential increase of babesiosis occurring in Lyme disease endemic regions. Babesiosis can be a severe infection in some individuals, often requiring hospitalization, and can cause death. Here we are generating a rapid diagnostic assay that will be capable of the simultaneous direct detection of babesiosis and serodiagnosis of Lyme disease from the same sample in under fifteen minutes at the point of care. This will support diagnosis and rapid treatment decisions for both babesiosis and Lyme disease, decreasing the potential for development of severe disseminated disease complications and improving patient outcomes.

PI_NAMEs: ARNABOLDI, PAUL MICHAEL;DATTWYLER, RAYMOND JAMES (contact);DI CARLO, DINO

PROGRAM_OFFICER_NAME: BOWDEN, NADINE

PROJECT_TERMS: accurate diagnosis;Affinity;Age Years;American;Anaplasmosis;Antibodies;antigen detection;Antigens;antimicrobial;Area;arm;assay development;Awareness;Babesia;Babesia microti;Babesiosis;Biological Assay;Birth;Blood;Blood specimen;Borrelia burgdorferi;Borrelia microti;Carrier State;Cause of Death;Characteristics;Child;Clinical;clinical diagnosis;co-infection;Communicable Diseases;cost;Detection;detection limit;detection method;detection platform;Development;Diagnosis;diagnostic assay;diagnostic development;Disease;disease transmission;Early treatment;Endemic Diseases;Ensure;Environment;Epitope Mapping;Epitopes;experience;Exposure to;Geographic Distribution;Health;Hospitalization;Hybridomas;Immunoassay;Immunodominant Antigens;Immunosuppression;improved;Incidence;Individual;Infection;Infectious Agent;innovation;Intervention;Laboratories;Lyme Disease;Lyme disease diagnosis;machine learning algorithm;Methods;Microscopy;Modality;Molecular Conformation;Monoclonal Antibodies;Mothers;Paper;Parasites;Parasitic infection;pathogen;Patient Care;Patient-Focused Outcomes;Patients;Peptides;Performance;Physicians;point of care;Predisposing Factor;prevent;prototype;rapid detection;Rapid diagnostics;rapid test;Reporter;Reporting;Research Personnel;Risk Factors;Sampling;Sensitivity and Specificity;Serology;Site;Spleen;System;Testing;tick transmission;Tick-Borne Diseases;Ticks;Time;Transfusion;transmission process;Treatment Protocols;Whole Blood

PROJECT_TITLE: A point of care vertical flow assay for the direct detection of Babesia microti and the serodiagnosis of Lyme disease.

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 DCAI-X (14)]


ORG_CITY: NEW HAVEN

ORG_NAME: YALE UNIVERSITY

PHR: PROJECT NARRATIVE: Although the measurement of gene expression is now a cornerstone of biological inquiry, current approaches have several limitations including poor detection of low-abundance transcripts, the need for tissue and cell- destructive processes and the production of static rather than continuous measurements. We propose a novel technology to measure gene expression that leverages the flexibility and power of CRIPSR-mediated transcriptional activation (CRISPRa) and set-encoded fluorescent multiplexing. We will apply this new approach to detect nine or more inflammatory cytokines dynamically over time and spatially in situ within tissues, laying the groundwork for new discoveries in tumor immunology and other fields.

PI_NAMEs: ISHIZUKA, JEFFREY J. (contact)

PROGRAM_OFFICER_NAME: DUECK, HANNAH RUTH

PROJECT_TERMS: Acute;Address;Antibodies;Automobile Driving;Biological;Biological Process;Biology;Cells;Clustered Regularly Interspaced Short Palindromic Repeats;Color;Complex;Cre-LoxP;CRISPR-mediated transcriptional activation;cytokine;design;design and construction;Detection;detection sensitivity;Disadvantaged;Enzyme-Linked Immunosorbent Assay;experimental study;Exposure to;flexibility;Flow Cytometry;Fluorescence;fluorophore;functional genomics;Gene Expression;Gene Targeting;Genes;Genetic;Genetic Transcription;Guide RNA;Heterogeneity;Housekeeping Gene;Immune;Immunofluorescence Immunologic;Immunotherapy;improved;In Situ;In Vitro;in vivo;Infiltration;Inflammation;Inflammation Mediators;Inflammatory;Inflammatory Response;insight;Investigation;Libraries;live cell imaging;Mammalian Cell;Measurement;Measures;Mediating;Membrane Proteins;Modeling;Molecular;multiplex detection;Mus;neoplastic cell;neuron development;new technology;novel;novel strategies;pathogen;Performance;Population;posttranscriptional;preservation;Process;Production;Property;protein biomarkers;protein expression;Randomized;Reagent;Recording of previous events;Regulation;Regulator Genes;repaired;Reporter;Reporter Genes;Reporting;response;Shapes;Signal Transduction;single-cell RNA sequencing;Site;Stains;Surface;System;Technology;Testing;Time;Tissues;tool;Transcript;Transcriptional Activation;tumor;Tumor Cell Line;tumor immunology;tumor microenvironment

PROJECT_TITLE: Multiplexed, Continuous Reporting of Gene Expression via CRISPR-mediated Transcriptional Activation

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 TCRB-D (M1)]


ORG_CITY: CHESTNUT HILL

ORG_NAME: BOSTON COLLEGE

ORG_STATE: MA

PHR: PROJECT NARRATIVE Growing evidence suggests that dysregulations in the RNA chemical modification landscapes strongly correlate with cancers. Tools that enable site-specific modulation of RNA modifications are critical to elucidate the function of RNA chemical modifications in biology and cancers; these tools provide basis for future development of genetic medicine targeting RNA chemical modifications. In this proposal, we aim to develop robust, efficient, and accurate editing tools for site-specifically installing the N6-methyladenosine on human mRNAs, via establishing a directed evolution platform to rapidly select high-performance N6-methyladenosine methyltransferases.

PI_NAMEs: NIU, JIA ;ZHOU, HUIQING  (contact)

PROGRAM_OFFICER_NAME: MAAS, STEFAN

PROJECT_TERMS: Acute Myelocytic Leukemia;base;Binding;Biology;Cancer Biology;cancer type;Cells;Chemicals;Clustered Regularly Interspaced Short Palindromic Repeats;Dependence;Development;Directed Molecular Evolution;Drug resistance;Endometrial Carcinoma;Endoribonucleases;Engineering;Enzymes;epitranscriptomics;Future;Genes;Genetic Medicine;Genetic Transcription;genomic locus;Genotype;Glioblastoma;Human;improved;In Situ;In Vitro;insight;interest;Libraries;Malignant Breast Neoplasm;Malignant Neoplasms;Maps;Measures;Mediating;Messenger RNA;Methods;Methylation;Methyltransferase;Modality;Modification;monomer;Mutation;Neoplasm Metastasis;Pathway interactions;Performance;Phenotype;Planet Mars;Play;Prognosis;Property;Proteins;Reader;Regulation;Relaxation;Resolution;Reverse Transcriptase Polymerase Chain Reaction;RNA;RNA Binding;RNA Sequences;Role;Site;Specificity;stoichiometry;Structure-Activity Relationship;System;Technology;technology platform;tool;Transcript;Translations;tumor;tumorigenesis;Variant

PROJECT_TITLE: Development of A Directed Evolution Platform for RNA Methyltransferases.


NIH_SPENDING_CATS: Behavioral and Social Science;Clinical Research;Health Services;Pediatric

ORG_CITY: NEW YORK

ORG_NAME: HATS & LADDERS, INC.

PHR: PROJECT NARRATIVE Despite long-standing efforts to diversify the health workforce, many Black and Latino/x adolescents lack the exposure, confidence and skills necessary to develop health career aspirations or to enact “health citizenship,” which are both prerequisites for equitable and effective public health. This project will design and develop a blended digital intervention––with a data-driven and gamified app, project-based activities, live career expert panels, mentoring sessions, and a toolkit for educators––to strengthen opportunities for under-represented youth to pursue health workforce careers and improve their overall health literacy.

PI_NAMEs: GONZALEZ, SONIA K;POTTER, LEAH  (contact)

PROJECT_TERMS: Adolescent;adolescent health;Algorithms;aspirate;Awareness;Benchmarking;Black race;Black, Indigenous, People of Color;career;Career Choice;Client;cognitive interview;Communities;Community Developments;community organizations;Curiosities;dashboard;Data;Databases;Decision Making;design;Development;digital;digital intervention;Ecology;Educational Curriculum;Educational process of instructing;Educational workshop;Effectiveness;Effectiveness of Interventions;efficacy testing;Equity;Evaluation;experience;Face;Feedback;Future;Goals;Health;Health education;Health Educators;health literacy;Health Occupations;Health Personnel;Health Professional;Healthcare;high school;Human;improved;innovation;inquiry-based learning;Instruction;interoperability;Intervention;Interview;Joints;Knowledge;Latino;Learning;literacy;Measures;Medicine;Mentors;Metadata;Methods;ninth grade;novel;operation;Outcome;Outcome Measure;Participant;peer coaching;Personal Satisfaction;Persons;Phase;pilot test;Problem Solving;programs;Progress Reports;prototype;Public Health;Race;Randomized, Controlled Trials;Recommendation;recruit;Reporting;Research;research and development;Respondent;role model;Sampling;Schools;Self Assessment;Self Efficacy;skills;Small Business Innovation Research Grant;Students;Surveys;tenth grade;Testing;Texas;Training;Universities;usability;Vocational Guidance;volunteer;Work;Youth

PROJECT_TITLE: Hats & Ladders for Health: Data-driven Decision-Making for Future Health Citizens and Professionals


ADMINISTERING_IC: MH

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Brain Disorders;Neurosciences

ORG_NAME: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC

PHR: Project Narrative Historically, astrocytes were considered support cells for neurons, but emerging data suggest that they are an integral part of what has traditionally been considered “neural” circuits. Astrocytes can both receive signals from neurons and release neuroactive signals. This transformative project will explore the provocative possibility that astrocytes integrate neuromodulator signals to affect circuit function throughout the brain.

PI_NAMEs: DRANOVSKY, ALEX  (contact)

PROGRAM_OFFICER_NAME: NADLER, LAURIE SUE

PROJECT_TERMS: Acetylcholine;Affect;Aging;Animals;Astrocytes;awake;Award;Behavior;Biomedical Engineering;Brain;brain cell;Calcium;Cell Physiology;Cells;cellular imaging;Central Nervous System Diseases;Chronic stress;Classification;Cognitive deficits;Communication;computational neuroscience;Data;design;Development;Disease;Dopamine;Exhibits;Extracellular Space;FDA approved;Functional disorder;Gene Expression;Genetic;Goals;Health;In Vitro;in vivo;innovation;insight;interest;Measures;Methods;Molecular;molecular targeted therapies;Morphology;multi-scale modeling;multiplexed imaging;neural circuit;Neuromodulator;Neuromodulator Receptors;neuronal circuitry;Neurons;Neurophysiology - biologic function;neuropsychiatric disorder;neuroregulation;Neurosciences;neurotransmission;Norepinephrine;novel strategies;Organ;Participant;pharmacologic;Physiological;Physiology;Population;Positioning Attribute;preservation;Process;Property;receptor;Reporting;Research;Research Personnel;response;Role;Scientist;segregation;sensor;Serotonin;serotonin receptor;Signal Transduction;Slice;Stress;Structure;study population;Supporting Cell;Synapses;System;Techniques;Technology;Testing;Tissues;transcriptomics;transmission process

PROJECT_TITLE: Astrocytes as the integrators of neuromodulator signals


NIH_SPENDING_CATS: Cancer;Genetics

ORG_CITY: INDIANAPOLIS

ORG_NAME: NERX BIOSCIENCES, INC.

ORG_STATE: IN

PHR: Project Narrative Health Relevance: The research described in this new application has direct relevance to human health in that we are proposing the development of novel therapeutic agents to be used in the treatment of human cancer. We will conduct research exploiting a novel mechanism to impact the DNA damage response to treat human cancer.

PI_NAMEs: PAWELCZAK, KATHERINE  (contact)

PROGRAM_OFFICER_NAME: BOZZA, WILLIAM PATRICK

PROJECT_TERMS: A-Form DNA;Acceleration;Address;Animals;anticancer activity;Biological Availability;Biological Sciences;cancer cell;Cancer Patient;cancer therapy;Canis familiaris;Cell Death Induction;Cell Survival;cGMP production;chemical synthesis;Chemicals;Chemistry;Clinical;Clinical assessments;commercialization;Critical Pathways;Data;Development;Disease;DNA Damage;DNA Repair;DNA Repair Pathway;DNA Single Strand Break;Dose;Drug Kinetics;Dryness;efficacy evaluation;efficacy study;Ensure;exhaustion;expectation;first-in-human;Formulation;Funding;genetic predictors;Genome Stability;Genomic Instability;Goals;Growth;Health;Human;Immunotherapy;In Vitro;in vivo;inhibitor;interest;Investigational Drugs;Licensing;Malignant neoplasm of lung;Malignant Neoplasms;manufacture;medication safety;Metabolism;Methodology;Modeling;Mus;Mutation;New Drug Approvals;novel;novel strategies;novel therapeutic intervention;novel therapeutics;Oncogenic;Oral;Outcome;Pathway interactions;patient population;Patient Selection;pharmacokinetics and pharmacodynamics;Pharmacologic Substance;Phase;phase I trial;Phosphotransferases;Poly(ADP-ribose) Polymerase Inhibitor;Population;Positioning Attribute;Process;Protein Kinase;Proteins;Rattus;Readiness;Regimen;replication factor A;replication stress;Research;response;Risk;Safety;safety assessment;safety study;Secure;sensor;Series;Signal Transduction;small molecule;SS DNA BP;success;synthetic lethal interaction;targeted agent;targeted cancer therapy;targeted treatment;Therapeutic;Therapeutic Agents;Toxicology;Treatment outcome;tumor;Work;Xenograft procedure

PROJECT_TITLE: Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CDPT-R (12)]